September 2021

KARIN PRZYKLENK, PH.D.

CONTACT INFORMATION:

Address:	University Health Center, 4201 St. Antoine, St. Suite 4A Detroit, MI. 48201 USA
Telephone:	313.745.9045 (Office) 774.253.0895 (Cell)
E-mail:	karin.p@cmich.edu

ACADEMIC AND PROFESSIONAL APPOINTMENTS:

06/2021 –	Scientific Director, CMU/University Pediatricians Clinical Research Institute, Carman and Ann Adams Endowed Chair in Pediatric Research, Children's Hospital of Michigan; Professor of Pediatric Science, Central Michigan University (CMU), Detroit MI
08/2021 –	Emerita Professor, Wayne State University School of Medicine, Detroit, MI
02/2008 – 06/2021	Professor (with Tenure), Departments of Physiology and Emergency Medicine; Associate Member, Center for Molecular Medicine & Genetics (05/2008), Wayne State University School of Medicine, Detroit, MI
02/2008 – 1/2020	Director, Cardiovascular Research Institute, Wayne State University School of Medicine, Detroit, MI
2002 – 01/2008	Professor, Emergency Medicine, Anesthesiology and Medicine (Cardiology); Faculty Member, Center for Platelet Function Studies, University of Massachusetts Medical School, Worcester, MA.

1988 - 2002	Assistant Director of Research and Director of Cardiac Function, Heart Institute, Hospital of the Good Samaritan, Los Angeles, CA.
1992 - 2002	Associate Professor of Research Medicine, Department of Medicine, Section of Cardiology, University of Southern California, Los Angeles, CA.
1988 - 1992	Assistant Professor of Research Medicine, Department of Medicine, Section of Cardiology, University of Southern California, Los Angeles, CA.
1986 - 1988	Assistant Professor, Department of Internal Medicine, Division of Cardiology, Wayne State University/Harper Hospital, Detroit, MI.

FELLOWSHIPS:

1985	Post-Doctoral Research Fellow, Department of Internal Medicine, Division of Cardiology, Wayne State University/Harper Hospital, Detroit, MI.
1983 - 1984	Post-Doctoral Research Fellow, Department of Medicine, Harvard Medical School, Boston, MA.

EDUCATION:

Sept 2017 - ongoing	Graduate Diploma in Management London School of Economics and Political Science, University of London, London, UK *Anticipated completion: June 2022*
1978 - 1982	Ph.D. Department of Biophysics, University of Western Ontario, London, Ontario, Canada.
1974 - 1978	B.Sc. (Honors) Physics and Biology University of Saskatchewan, Saskatoon, Saskatchewan, Canada.

HONORS AND AWARDS:

2021	Recognized as an Expertscape.com World Expert in Myocardial Reperfusion Injury https://www.expertscape.com/ex/myocardial+reperfusion+injury
2019	American Journal of Physiology – Heart & Circulatory Physiology *"Best Paper Award 2018: Review Article"* for the manuscript "Guidelines for experimental models of myocardial ischemia and infarction" published April 2018
2014	*"Outstanding Faculty Mentor Award"* Wayne State University School of Medicine
June 2004	Visiting Scientist, UMASS – Sapporo Medical University Academic Exchange Program: Hosted by 2nd Department of Internal Medicine (Drs. Miura & Shimamoto) Sapporo Medical University.
July 2000	20th Anniversary: 'Best of' *Cardiovascular Reviews and Reports* for the manuscript "Recent advances in stunned myocardium", originally published October 1987 and updated June 1990.
1992	*"People Who Make a Difference"* Research Highlights of the American Heart Association (Greater Los Angeles Affiliate).
June 1990	Master Teacher Award from *Cardiovascular Reviews and Reports* for the manuscript "Recent advances in stunned myocardium", originally published October 1987 and updated June 1990.
1983 - 1985	Medical Research Council of Canada Post-Doctoral Fellowship Award
1978 - 1982	Medical Research Council of Canada Graduate Studentship Award

MEMBERSHIPS AND SOCIETIES:

American Heart Association: Basic Cardiovascular Sciences Council

The Physiological Society

Invited Honorary Member, Cellular Biology Working Group, European Society of Cardiology

SCIENTIFIC COMMITTEES, STUDY SECTIONS AND OTHER ACADEMIC ACTIVITIES:

2021-	Member, Romanian National Research Council Grants Evaluation Committee
2017-	Member, European Research Council (ERC) Starting Grants Evaluation Committee
2018-	Ad hoc Member, NIH Review Panel for Small Business: Cardiovascular Sciences ZRG1 CVRS-C (10)
2018, 2019	External grant reviewer: Austrian Science Fund; Swiss National Science Foundation; Health Research Board-Ireland
2018	Invited Participant, NIH Center for Scientific Review (CSR): Program Evaluation of NIH Peer Review Processes: The Role of Anonymization
2017-2018	Member, American Physiological Society (APS)/American Journal of Physiology (AJP) Writing Group: 'Animal Models of Myocardial Ischemia and Infarction'
2010-2016	Member, Protocol Review and Monitoring Committee (PRMC), NIH/NHLBI Preclinical Consortium to Facilitate Translation and Cardioprotective Therapies (CAESAR)
2010-2016	Member, NIH/NHLBI Myocardial Ischemia and Metabolism (MIM) Study Section
2015	External grant reviewer: Diabetes UK
2014	Member, NIH/NHLBI Special Emphasis Panel: PPG Review
2014	External grant reviewer: British Heart Foundation
2012	Chair of scientific session "Protection of Ischemic Myocardium IV" at the 2012 Scientific Sessions of the American Heart Association, Los Angeles CA.
2012	Chair of scientific session "Cardioprotection in the Presence of Cardiovascular Risk Factors" at the 75th Anniversary of Albert Szent- Györgyi's Nobel Prize Award, March 22nd-25th 2012, Szeged Hungary
2011	Chair of oral session "Novel strategies in myocardial protection" at the 9th International Congress on Coronary Artery Disease, Venice Italy
2011-2012	External grant reviewer: HRB (Health Research Board-Ireland)
2011	External grant reviewer: HRUK (Heart Research-United Kingdom)
2010-2011	External grant reviewer: Ontario Research Fund
2010	Member, NIH/NHLBI Workshop: New Horizons in Cardioprotection September 20th-21st 2010, Bethesda MD
2010	Moderator of poster session "Risk factors for cardiac events" at the XX World Congress, International Society for Heart Research, Kyoto Japan

2010	Invited Judge, Inaugural Graduate School Exhibition, Wayne State University, Detroit MI.
2009-2010	External grant reviewer: Alberta Heritage Foundation for Medical Research
2009	Chair of scientific session "Experimental Myocardial Infarction: Cell Therapy, Remodeling, Cardioprotection" at the 2009 Scientific Sessions of the American Heart Association, Orlando FL.
2009	Ad hoc member, NIH/NHLBI Myocardial Ischemia and Metabolism (MIM) Study Section
2008	Organizing Committee and Session Chair, Cardioprotection and its Clinical Application: 14th International Symposium November 8th 2008, New Orleans, LA
2008	Chair of Plenary Session "Modulation of Ischemia-Reperfusion Injury: Novel Biomarkers" at the 14th World Congress on Heart Disease, July 28th-31st 2008, Toronto, Canada.
2008	Invited Judge, Annual Research Symposium of Henry Ford Health System, Detroit MI.
2008	Member, NIH/NHLBI Special Emphasis Panel: ZRG1 CVS-K(02)
2007	Chair of scientific session "New Advances in Cardioprotection" at the 56th Annual Scientific Sessions of the American College of Cardiology, New Orleans LA.
2007	Distinguished Correspondent, Sociedad Iberoamericana de Información Científica (SIIC) Program of Scientific Bureaus
2007	Ad hoc external consultant: Senior Appointments and Promotions Committee, University of Connecticut School of Medicine
2006, 2009, 2010	Abstract grader for the World Congress of Cardiology/European Society of Cardiology Congress
2005-2007	Member, Grants Committee, Society for Academic Emergency Medicine
2005-2007	External grant reviewer: Biomedical Research Council of Singapore.
2004-2005	Member, NIH/NHLBI Review Panel: Program Project P01 HL080103
2004	External grant reviewer: Wellcome Trust, London UK.
2004	Member, NIH/NHLBI Special Emphasis Panel: ZRG1 CVS-F(04)
2004-2008	Abstract grader for the Annual Scientific Sessions of the Society for Academic Emergency Medicine
2003-2014	Scientific Executive Committees, International Academy of Cardiology and Annual Meeting of the World Congress on Heart Disease

2003-2009	Abstract grader for the Annual Scientific Sessions of the American College of Cardiology
1993-2000; 2003-2010	Abstract grader for the Annual Scientific Sessions of the American Heart Association
2003	Member, Cardiovascular (Patho)Physiology II Study Section, American Heart Association (National)
2002	Ad hoc member, CVA Study Section, NIH/NHLBI (March 2002)
2000	Chair of scientific session “Signaling Pathways in Preconditioning” at the 73rd Annual Scientific Sessions of the American Heart Association, New Orleans LA.
1998	Chair of scientific session “Apoptosis in Myocardial Ischemia” at the 71st Annual Scientific Sessions of the American Heart Association, Dallas TX
1997-1998	International Advisory Committee for the conference “Heart in Stress”, June 28 - July 3 1998, Lahti Finland
1997	Chair of scientific session “Mechanisms of Ischemic Preconditioning II” at the 70th Annual Scientific Sessions of the American Heart Association, Orlando FL.
1997, 1998	External grant reviewer: Jewish Hospital Foundation, Louisville, KY.
1996	Chair of scientific session "Mechanisms of Ischemic Preconditioning" at the 69th Annual Scientific Sessions of the American Heart Association, New Orleans, LA.
1996	Judge, Laverna Titus Young Investigators Forum, American Heart Association (Greater Los Angeles Affiliate)
1995	External grant reviewer: Heart and Stroke Foundation of Canada.
1995	Chair of scientific session "Preconditioning and Stunning" at the 44th Annual Scientific Sessions of the American College of Cardiology, New Orleans LA.
1995	Chair, Laverna Titus Young Investigators Forum, American Heart Association (Greater Los Angeles Affiliate)
1993	Chair of moderated poster session "Stunned myocardium" at the 66th Annual Scientific Sessions of the American Heart Association, Atlanta GA.
1991	Chair of scientific session "Ischemic Preconditioning" at the 64th Annual Scientific Sessions of the American Heart Association, Anaheim CA.
1991	Study Session, National Merit Review, Board for Cardiology, Department of Veterans Affairs
1988-1995	Fellowship/Clinician-Scientist/Investigative Group Study Sections, American Heart Association (Greater Los Angeles Affiliate)

ADMINISTRATIVE COMMITTEES:

2021 -	Member, Research Advisory Council Central Michigan University
2021	Member, Institutional Review Board (IRB) Task Force Central Michigan University
2021	Member, Executive Committee Department of Physiology, Wayne State University School of Medicine *Charged with supporting and advising the Interim Chair on the overall management of the Department*
2021	Member, Physiology Academic Program Review Committee Department of Physiology, Wayne State University School of Medicine *Charged with leading preparations for the upcoming university-mandated Departmental Academic Program Review*
2020-2021	Chair, Curriculum Committee Department of Physiology, Wayne State University School of Medicine
2019-2021	Member, Task Force Curriculum development for new MSc in Medical Physiology Wayne State University School of Medicine
2019-2021	Member, MD-PhD Admission Interview Committee Wayne State University School of Medicine
2016-2021	Member, Executive Committee of the Wayne State University School of Medicine Faculty Council on Philanthropy
2015-2016	Member, Review Advisory Panel for the 7-Year Academic Program Review of the Department of Anatomy and Cell Biology Wayne State University School of Medicine
2011-2012	Member, Translational Research Working Group Member, Core Facilities Working Group (Laboratory Animal Resources Sub-committee), Wayne State University School of Medicine Research Strategic Planning
2009-2021	Member, Institutional Animal Care and Use Committee, Wayne State University (Full Member: 2009-2011; Alternate: 2011-2021)
2009-2021	Member, Promotions and Merit Review Committee (2009-2021), Member, Budget Committee (2014-2021) Department of Emergency Medicine, Wayne State University School of Medicine
2008-2021	Member, Promotion and Tenure Committee (2020-2021; 2008-2009) Member, Graduate Committee (2019-2021) Member, Research Committee (2017-2018) Member, Budget Committee (2008-2015) Member, Faculty Search Committee (2008-2012) Department of Physiology, Wayne State University School of Medicine

2007-2008	Member, Faculty Development Advisory Council, University of Massachusetts Medical School
2007	Member, Search Committee for Chair of Quantitative Health Sciences, University of Massachusetts Medical School
2006-2008	Member, Faculty Promotion-Personnel Action Committee, University of Massachusetts Medical School
2003-2008	Chair (2005-08) and Member (2003-08), Departmental Promotion-Personnel Action Committee, Department of Emergency Medicine, University of Massachusetts Medical School
1997-2002	Member, Governing Board, California Biomedical Research Association
1997	Member, Budget Planning Task Force. American Heart Association (Greater Los Angeles Affiliate)
1994-1998	Member, Finance & Administration Committee, Member, Research Committee, American Heart Association (Greater Los Angeles Affiliate)
1993, 1994	Vice Chair, Investigative Group Study Session, American Heart Association (Greater Los Angeles Affiliate)

SCIENTIFIC CONSULTANT / ADVISOR:

2012-	LifeCuff Technologies, Inc. (formerly Infarct Reduction Technologies, Inc.), Philadelphia PA
2009-2018	GLSynthesis, Inc., Worcester MA.
1994-2000	RIBI ImmunoChem Research, Inc., Hamilton MT

JOURNAL RESPONSIBILITIES:

2019 -	Editor-in-Chief, *Journal of Cardiovascular Pharmacology and Therapeutics*
2016-2017	Guest Editor, *Journal of Cardiovascular Pharmacology and Therapeutics* Focused issue on 'The Future of Remote Ischemic Conditioning': Part I [22(4)] and Part II [22(5)]
2015	Invited Reviewer, American Heart Association Scientific Statements, *Circulation*
2014-2018	Judge, *Experimental Physiology* Review Prize
2013-2018	Senior Editor, *Experimental Physiology*
2000 -	Editorial Board Member, *International Journal of Molecular Science* (2021 - ongoing); *Circulation Research* (2013 – ongoing); *Basic Research in Cardiology* (2000 – ongoing); *Journal of Cardiovascular Pharmacology and Therapeutics* (2009 – 2018); *Circulation* (2000 – 2016)*; Current Cardiology Reviews (*2005 – ongoing); *Journal of Heart Disease* (2005 – ongoing)
1999	Guest Editor, *Journal of Thrombosis and Thrombolysis* Focused Issue on 'Cardioprotection with sodium-hydrogen exchange inhibition': 8(1).
1997	Guest Editor, *Journal of Thrombosis and Thrombolysis* Focused Issue on 'Lethal Myocardial Reperfusion Injury': 4(1).
1995-2017	Associate Editor, *Journal of Thrombosis and Thrombolysis*
1987 -	Review manuscripts for *Circulation Research; Circulation; Nature; The Lancet; New England Journal of Medicine; Journal of the American College of Cardiology; Academic Emergency Medicine; American Journal of Cardiology; Cardiovascular Research; Basic Research in Cardiology; Journal of Molecular and Cellular Cardiology; American Journal of Physiology; Journal of Applied Physiology; Cardiovascular Drugs & Therapy; Coronary Artery Disease; Journal of Pharmacology and Experimental Therapeutics, PLOS One*

TEACHING RESPONSIBILITIES:

Wayne State University

2009 - ***Mentor/supervisor for PhD candidates***

Yi Dong: Department of Physiology
2009-2014 (PhD awarded June 2014)
Recipient of Best Poster Award at the American Society for Biochemistry & Molecular Biology (ASBMB) Special Symposium "Mitochondria: Energy, Signals and Homeostasis"
June 2012
Recipient of American Heart Association Travel Award
November 2013

Christian A. Reynolds: Department of Physiology
[Co-mentored with Thomas Sanderson, PhD]
2011-2015 (PhD awarded June 2015)
Recipient of American Heart Association Predoctoral Fellowship Award: July 2012-June 2014

Joseph Wider: Department of Physiology
2012-2017 (PhD awarded March 2017)
Recipient of NIH T32 Detroit Cardiovascular Training Program Predoctoral Fellowship Award
January 2015-December 2017

Anthony Anzell: Department of Physiology
[Co-mentored with Thomas Sanderson, PhD]
2015-2020 (PhD awarded April 2020)

Andrew Kulek: Department of Biochemistry & Molecular Biology
MD-PhD Student
Recipient of NIH T32 Detroit Cardiovascular Training Program Predoctoral Fellowship Award
2015 – ongoing

Member of PhD Advisory Committee

Victoria McIntosh: Department of Physiology
2008-2012 (PhD awarded March 2012)

Enbo Zhan: Department of Physiology
2012-2014 (PhD awarded July 2014)

Yu Yang: Department of Physiology
2014-2016 (PhD awarded December 2016)

Beth Meier: Department of Biomedical Engineering
2014-2017 (PhD awarded February 2017)

Kevin Miles: Department of Chemical Engineering
2016-2017 (PhD awarded July 2017)

Fika Tri Anggraini: Department of Physiology
2014-2017 (PhD awarded October 2017)

Judith Ingalls: Department of Physiology
2015-2018 (PhD awarded March 2018)

Christos Strubakos: Department of Physiology
2015-2018 (PhD awarded August 2018)

Abhinav Krishnan: Department of Physiology
2019-2021 (PhD awarded June 2021)

Deena Damschroder: Department of Physiology
2018 – ongoing

Bipridas Roy: Department of Physiology
2019 – ongoing

Tyler Cobb: Department of Physiology
2019 – ongoing

Member of MS Thesis Committee

Enbo Zhan: Department of Physiology
MS awarded May 2011

Fika Tri Anggraini: Department of Physiology
MS awarded April 2014

Lesley Calo: Department of Physiology
MS awarded May 2015

Melissa Bukowski: Department of Physiology
MS awarded August 2016

Sponsor for applicant: Sarnoff Fellowship Program

Milan Kaushik: M2 Medical Student
2017 – 2018
Recipient of 2018-19 Sarnoff Fellowship

Mentor for BMS students

Melanie Jamel
Primary advisor for BMS Thesis
'Advances in cardiosphere-derived cell therapy: Cardiomyocyte regeneration and implications on the future of ischemic cardiomyopathy'
Masters in Basic Medical Sciences (BMS): pending (tentatively May 2020)

Geoffrey Ginter
Primary advisor for BMS Thesis
'Myocardial ischemia-reperfusion injury'
Masters in Basic Medical Sciences (BMS) awarded August 2018

Benjamin Lehr
Primary advisor for BMS Thesis
'Ischemic postconditioning: limiting damage in myocardial infarction'
Masters in Basic Medical Sciences (BMS) awarded May 2014

Mentor/supervisor for undergraduate students

Osadayi Ireuosa Ohanmu: Biology, University of Massachusetts-Amherst
May 2018 – August 2018
Recipient of 2020-21 NIH PREP Scholar Award, University of Illinois-Chicago Post Baccalaureate Research Education Program

Edward Hill: Philosophy/Natural Science, Xavier University, Cincinnati
June 2017 – August 2017

Jeremy Amayo: Department of Biology, Wayne State University
November 2011 – May 2013
Recipient of "Wayne State University Undergraduate Research & Creative Projects Award"
May 2012
Recipient of "Best Poster Award" for the presentation 'EM Physician Stress and Patient Care: A Pilot Study' at the Wayne State University Undergraduate Research Conference"
February 2013

Invited External Dissertation Examiner

2017	External Examiner Aarhus University, Aarhus Denmark PhD Candidate: Kasper Pryds
2012	Overseas External Examiner RMIT University, Melbourne Australia PhD Candidate: Sapha Mosawy

Didactic Lectures

2020-2021	Cardiopulmonary Physiology: Case-Based Learning 4 lectures per year (6 contact hours)
2019	FPH 7120: "Global Public Health" Invited participant in 1 lecture (1 contact hour)
2013-2015	Endocrine T32 Training Course: "Concepts, Methods and Path to Endocrine Research" 1 lecture per year (2 contact hours)
2008-2020	PSL 7600: "Advanced Cardiovascular Physiology" 2 lectures per year (4 contact hours); Advisor for PSL 7600 student research papers (2-4 students per year)

University of Massachusetts Medical School, Worcester MA

2003-2008 Mentor/supervisor for fellows and junior faculty in the Emergency Medicine Research Laboratories, University of Massachusetts Medical School.
Fellows/mentees: Eric W. Dickson, MD, Matthew D. Linden, PhD, Chad E. Darling, MD, Craig Smith, MD, Marie Mullen, MD
Drs. Dickson and Darling: recipients of NIH K08 (Mentored Clinical Scientist Research Career Development) Awards

Good Samaritan Hospital, Los Angeles CA

1989-2002 Mentor/supervisor for post-doctoral fellows in the Heart Institute Research Laboratory, Good Samaritan Hospital.
Fellows: Michel Ovize, MD; Barbara Bauer, MD; Katsuya Hata, MD PhD; Anne Gysembergh, PhD; Guohu Li, MD

BIBLIOGRAPHY

Current h-index = 53

PEER-REVIEWED PUBLICATIONS:

1. **Przyklenk K,** Groom AC. Microvascular evidence for a `transition zone' around a chronic myocardial infarct in the rat. *Can J Physiol Pharmacol* 1983; 61: 1516-1522.

2. **Przyklenk K,** Groom AC. Can exercise promote revascularization in the transition zone of infarcted rat hearts? *Can J Physiol Pharmacol* 1984; 62: 630-633.

3. **Przyklenk K,** Groom AC. Effect of exercise frequency, intensity and duration on revascularization in the transition zone of infarcted rat hearts. *Can J Physiol Pharmacol* 1985; 63: 273-278.

4. **Przyklenk K,** Vivaldi MT, Arnold JMO, Schoen FJ, Kloner RA. Capillary anastomoses between the left anterior descending and circumflex circulations in the canine heart: possible importance during coronary artery occlusion. *Microvasc Res* 1986; 31: 54-65.

5. **Przyklenk K**, Vivaldi MT, Arnold JMO, Schoen FJ, Kloner RA. Salvage of ischemic myocardium by reperfusion: importance of collateral blood flow and oxygen demand during occlusion. *Cardiovasc Res* 1986; 20: 403-414.

6. **Przyklenk K,** Kloner RA. Superoxide dismutase plus catalase improve contractile function in the canine model of the stunned myocardium. *Circ Res* 1986; 58: 148-156.

7. Arnold JMO, Antman EM, **Przyklenk K**, Braunwald E, Sandor T, Vivaldi MT, Schoen FJ, Kloner RA Differential effects of reperfusion on incidence of ventricular arrhythmias and recovery of ventricular function at 4 days following coronary occlusion. *Am Heart J* 1987; 113: 1055-1065.

8. **Przyklenk K,** Kloner RA. Effect of oxygen-derived free radicals on infarct size following six hours of permanent coronary artery occlusion: salvage or delay of myocyte necrosis? *Basic Res Cardiol* 1987; 82: 146-158.

9. **Przyklenk K**, Connelly CM, McLaughlin RJ, Kloner RA, Apstein CS. Effect of myocyte necrosis on strength, strain and stiffness of isolated myocardial strips. *Am Heart J* 1987; 114: 1349-1359.

10. **Przyklenk K,** Kloner RA. Acute effects of hydralazine and enalapril on contractile function of postischemic stunned myocardium. *Am J Cardiol* 1987; 60: 934-936..

11. **Przyklenk K,** Kloner RA. Diastolic abnormalities of postischemic stunned myocardium. *Am J Cardiol* 1987; 60: 1211-1213.

12. **Przyklenk K,** Kloner RA. Effect of verapamil on postischemic stunned myocardium: importance of the timing of treatment. *J Am Coll Cardiol* 1988; 11: 614-623.

13. **Przyklenk K,** Kloner RA. "Reperfusion injury" by oxygen-derived free radicals? Effect of superoxide dismutase plus catalase, given at the time of reperfusion, on myocardial infarct size, contractile function, coronary microvasculature and regional myocardial blood flow. *Circ Res* 1989; 64: 86-96.

14. **Przyklenk K,** Ghafari GB, Eitzman DT, Kloner RA. Nifedipine administered after reperfusion ablates systolic contractile dysfunction of postischemic stunned myocardium. *J Am Coll Cardiol* 1989; 13: 1176-1183.

15. **Przyklenk K.** Effect of chronic ibuprofen therapy on healing of experimentally-induced acute myocardial infarction in dogs. *Am J Cardiol* 1989; 63: 1146-1148.

16. Reddy BR, Kloner RA, **Przyklenk K.** Early treatment with the iron chelator deferoxamine limits infarct size in a canine model of coronary occlusion and reperfusion. *Free Radical Biol Med* 1989; 7: 45-52.

17. **Przyklenk K,** Kloner RA. Is stunned myocardium a protective mechanism? Effect of acute alterations in myocardial oxygen demand on recovery of contractile function and high energy phosphate stores at 1 day post-reperfusion. *Am Heart J* 1989; 118: 480-489.

18. Kloner RA, **Przyklenk K,** Whittaker P. Deleterious effects of oxygen radicals in ischemia/reperfusion: resolved and unresolved issues. *Circulation* 1989; 80: 1115-1127.

19. **Przyklenk K,** Whittaker P, Kloner RA. In vivo infusion of free radical substrates causes myocardial systolic, but not diastolic, dysfunction. *Am Heart J* 1990; 119: 807-815.

20. Whittaker P, Boughner DR, Kloner RA, **Przyklenk K.** Stunned myocardium and collagen damage: differential effects of single and repeated occlusions. *Am Heart J* 1991; 121: 434-441.

21. **Przyklenk K,** Kloner RA. Angiotensin converting enzyme inhibitors improve contractile function of stunned myocardium by different mechanisms of action. *Am Heart J* 1991; 121: 1319-1330.

22. Reddy BR, Wynne J, Kloner RA, **Przyklenk K.** Pretreatment with the iron chelator deferoxamine fails to provide sustained protection against myocardial ischemia/reperfusion injury. *Cardiovasc Res* 1991; 25: 711-718.

23. **Przyklenk K**, Bauer B, Kloner RA. Reperfusion of "hibernating" myocardium: contractile function, high energy phosphate content and myocyte injury following 3 hours of sublethal ischemia and 3 hours of reperfusion in the canine model. *Am Heart J* 1992; 123: 575-588.

24. Ovize M, Kloner RA, Hale SL, **Przyklenk K.** Coronary cyclic flow variations "precondition" the ischemic myocardium. *Circulation* 1992; 85: 779-787.

25. Ovize M, **Przyklenk K**, Hale SL, Kloner RA. Preconditioning does not attenuate myocardial stunning. *Circulation* 1992; 85: 2247-2254.

26. Ovize M, **Przyklenk K**, Kloner RA. Partial stenosis is sufficient, and complete reperfusion is mandatory, to induce preconditioning. *Circ Res* 1992; 71: 1165-1173.

27. **Przyklenk K**, Bauer B, Ovize M, Kloner RA, Whittaker P. Regional ischemic "preconditioning" protects remote virgin myocardium from subsequent sustained coronary occlusion. *Circulation* 1993; 87: 893-899.

28. Simkhovich BZ, Hale SL, Ovize M, **Przyklenk K**, Kloner RA. Ischemic preconditioning and long chain acyl carnitine in the canine heart. *Coronary Artery Dis* 1993; 4: 387-392.

29. **Przyklenk K**, Kloner RA. Oxygen radical scavenging agents as "adjuvant therapy" with tissue plasminogen activator in a canine model of coronary thrombolysis. *Cardiovasc Res* 1993; 27: 925-934.

30. Whittaker P, Kloner RA, **Przyklenk K.** Laser-mediated transmural myocardial channels do not salvage ischemic myocardium. *J Am Coll Cardiol* 1993; 22: 302-309.

31. Bauer B, Simkhovich B, Kloner RA, **Przyklenk K.** Does preconditioning protect the coronary vasculature from subsequent ischemia/reperfusion injury? *Circulation* 1993; 88:659-672.

32. Ovize M, Kloner RA, **Przyklenk K.** Stretch preconditions the canine myocardium. *Am J Physiol* 1994; 266: H137-H146.

33. Whittaker P, **Przyklenk K.** Reduction of infarct size with ischemic preconditioning: mathematical evidence for protection via non-ischemic tissue. *Basic Res Cardiol* 1994; 89: 6-15.

34. **Przyklenk K.** Nicotine exacerbates postischemic contractile dysfunction of stunned myocardium in the canine model: possible role of free radicals. *Circulation* 1994; 89: 1272-1281.

35. **Przyklenk K,** Aoki A, Bellows S, Kleindienst D, Zubiate P Jr, Hale SL, Simkhovich BZ, Kloner RA, Kay GL. Stunned myocardium following prolonged cardiopulmonary bypass: Effect of warm vs. cold cardioplegia in the canine model. *J Cardiac Surg* 1994; 9: 506-516.

36. **Przyklenk K,** Simkhovich BZ, Bauer B, Kloner RA. Deterioration in myocardial blood flow following relief of sustained ischemia is not associated with release of endothelin into the coronary sinus. *Basic Res Cardiol* 1994; 89: 260-269.

37. Kloner RA, Shook T, **Przyklenk K,** Davis VG, Junio L, Matthews RV, Burstein S, Gibson M, Poole K, Cannon CP, McCabe C, Braunwald E, and the TIMI-4 Investigators. Previous angina alters in-hospital outcome in TIMI-4: A Clinical correlate to preconditioning? *Circulation* 1995; 91: 37-47.

38. **Przyklenk K,** Ovize M, Bauer B, Kloner RA. Gender does not influence the pathophysiology of acute myocardial infarction in dogs. *Am Heart J* 1995; 129: 1108-1113.

39. **Przyklenk K**, Kloner RA. Low dose IV acetylcholine acts as a "preconditioning-mimetic" in the canine model. *J Cardiac Surg* 1995; 10: 389-395.

40. **Przyklenk K,** Sussman MA, Simkhovich BZ, Kloner RA. Does ischemic preconditioning trigger translocation of protein kinase C in the canine model? *Circulation* 1995; 92: 1546-1557.

41. Simkhovich BZ, Whittaker P, **Przyklenk K,** Kloner RA. Transient pre-ischemic acidosis protects the isolated rabbit heart subjected to 30 minutes, but not 60 minutes, of global ischemia. *Basic Res Cardiol* 1995; 90: 397-403.

42. Whittaker P, Kloner RA, **Przyklenk K.** Intramyocardial injections and protection against myocardial ischemia: An attempt to explain the cardioprotective actions of adenosine. *Circulation* 1996; 93:2043-2051.

43. **Przyklenk K,** Zhao L, Kloner RA, Elliott GT. Reduction of infarct size with ischemic preconditioning and MLA: role of adenosine regulating enzymes? *Am J Physiol* 1996; 271: H1004-H1014.

44. Simkhovich BZ, **Przyklenk K,** Hale SL, Patterson M, Kloner RA. Direct evidence that preconditioning does not cause protein kinase C translocation in rabbit heart. *Cardiovasc Res* 1996; 32: 1064-1070.

45. **Przyklenk K**, Hata K, Zhao L, Kloner RA, Elliott GT. Disparate effects of preconditioning and MLA on 5' nucleotidase and adenosine levels during coronary occlusion. *Am J Physiol* 1997; 273: H945-H951.

46. **Przyklenk K,** Hata K, Kloner RA. Is calcium a mediator of infarct size reduction with preconditioning in canine myocardium? *Circulation* 1997; 96: 1305-1312.

47. Hata K, Whittaker P, Kloner RA, **Przyklenk K.** Brief antecedent ischemia attenuates platelet-mediated thrombosis in damaged and stenotic canine coronary arteries: role of adenosine. *Circulation* 1998; 97: 692-702.

48. Kloner RA, Shook T, Antman EM, Cannon CP, **Przyklenk K,** McCabe CH, Braunwald E, and TIMI 9B Investigators. Prospective temporal analysis of the onset of preinfarct angina versus outcome: an ancillary study in TIMI 9-B. *Circulation* 1998;97: 1042-1045

49. Simkhovich BZ, Kloner RA, **Przyklenk K.** Time course of protein kinase C translocation in globally ischemic rabbit heart. *Basic Res Cardiol* 1998; 93: 122-126.

50. Kloner RA, **Przyklenk K,** Shook T, Cannon C. Protection conferred by preinfarct angina is manifest in the aged heart: evidence from the TIMI-4 trial. *J Thromb Thrombolysis* 1998; 6: 89-92.

51. Bauer B, Simkhovich BZ, Kloner R.A, **Przyklenk K.** Preconditioning-induced cardioprotection and release of the second messenger inositol (1,4,5)-trisphosphate are both blocked by neomycin in rabbit heart. *Basic Res Cardiol* 1999; 94: 31-40.

52. Hata K, Kloner RA, Whittaker P, **Przyklenk K.** Brief myocardial ischemia attenuates platelet aggregation in remote, damaged and stenotic carotid arteries via an adenosine-mediated mechanism. *Circulation* 1999; 100: 843-848.

53. Dickson EW, Lorbar M, Porcaro WA, Fenton R, Reinhardt C, Gysembergh A, **Przyklenk, K.** Rabbit heart can be 'preconditioned' via transfer of coronary effluent. *Am J Physiol* 1999; 277: H2451-H2457.

54. Gysembergh A, Lemaire S, Sportouch C, Piot C, Richard S, Kloner RA, **Przyklenk K.** Pharmacologic manipulation of inositol (1,4,5)-trisphosphate signaling mimics preconditioning in rabbit heart. *Am J Physiol* 1999; 277: H2458-H2469.

55. **Przyklenk K,** Hata K, Whittaker P, Elliott GT. Monophosphoryl lipid A: a novel nitric oxide-mediated therapy to attenuate platelet aggregation? *J. Cardiovasc Pharmacol* 2000; 35: 366-375.

56. Dickson EW, Porcaro WA, Fenton R, Heard SO, Reinhardt C, Renzi FP, **Przyklenk K.** "Preconditioning at a distance" in the isolated rabbit heart. *Acad Emergency Med* 2000; 7: 311-317.

57. **Przyklenk K,** Whittaker P. Brief antecedent ischemia enhanced recombinant tissue plasminogen activator-induced coronary thrombolysis by adenosine-mediated mechanism. *Circulation* 2000; 102: 88-95.

58. **Przyklenk K,** Kloner RA. Sildenafil citrate (Viagra™) does not exacerbate myocardial ischemia in canine models of coronary artery thrombosis. *J Am Coll Cardiol* 2001; 37: 286-292.

59. Gysembergh A, Kloner RA, **Przyklenk K.** p38 MAPK activity is not increased early during sustained coronary occlusion in preconditioned versus control rabbit heart. *J Mol Cell Cardiol* 2001; 33: 681-690.

60. Gysembergh A, Kloner RA, **Przyklenk K.** The gap junction uncoupler heptanol does not limit ischemia-induced necrosis in rabbit heart. *Cardiovasc Pathol* 2001; 10: 13-17.

61. Horn M, Weidensteiner C, Scheffer H, Meininger M, de Groot M, Remkes H, Dienesch C, **Przyklenk K,** von Klein M, Neubauer S. Detection of myocardial viability based on measurements of sodium content: a ^{23}Na-NMR study. *Magn Reson Med* 2001; 45: 756-764.

62. Dickson EW, Blehar DJ, Carraway RE, Heard SO, Steinberg G, **Przyklenk K.** Naloxone blocks transferred preconditioning in isolated rabbit hearts. *J Mol Cell Cardiol* 2001; 33: 1751-1756.

63. **Przyklenk K,** Li G, Whittaker P. No loss in the *in vivo* efficacy of ischemic preconditioning in middle-aged and old rabbits. *J Am Coll Cardiol* 2001; 38: 1741-1747.

64. Kloner RA, Poole K, Shook T, **Przyklenk K**, Peritt K, Cannon C. Comparison of acute myocardial infarct size in patients ≥ 65 years versus < 65 years in the prethrombolytic period versus the thrombolytic period. *Am J Cardiol* 2002; 89: 1291-1293.

65. Tubbs RJ, Porcaro WA, Lee W J, Blehar DJ, Carraway RE, **Przyklenk K**, Dickson EW. Delta opiates increase ischemic tolerance in isolated rabbit jejunum. *Acad Emerg Med*. 2002; 9: 555-560.

66. Li G, Whittaker P, Yao M, Kloner RA, **Przyklenk K.** The gap junction uncoupler heptanol abrogates infarct size reduction with preconditioning in mouse heart. *Cardiovasc Pathol* 2002; 11: 158-165.

67. Dickson EW, Tubbs RJ, Porcaro WA, Lee W J, Blehar DJ, Carraway RE, Darling C, **Przyklenk K.** Myocardial preconditioning factors evoke mesenteric ischemic tolerance via opioid receptors and K_{ATP} channels. *Am J Physiol* 2002; 283: H22-H28.

68. **Przyklenk K,** Li G, Simkhovich BZ, Kloner RA. Mechanisms of preconditioning are age-related: protein kinase C-ε does not play a requisite role in old rabbits. *J Appl Physiol* 2003; 95: 2563-2569.

69. Dickson EW, Whittaker P, Darling CE, Hirsch DJ, Blehar DJ, **Przyklenk K.** Brief anoxia induces myocardial ischemic tolerance by an opioid-independent mechanism. *Cardiovasc Pathol* 2004; 13: 225-229.

70. Colantonio DA, Van Eyk JE, **Przyklenk K.** Stunned peri-infarct canine myocardium is characterized by degradation of troponin T, not troponin I. *Cardiovasc Res* 2004: 63; 217-225.

71. **Przyklenk K,** Whittaker P. *In vitro* platelet responsiveness to adenosine-mediated 'preconditioning' is age-dependent. *J Thromb Thrombolysis* 2005; 19: 5-10.

72. **Przyklenk K,** Maynard M, Darling CE, Whittaker P. Infarct size reduction with D-*myo*-inositol trisphosphate: initial evidence for a functional association between gap junctions and inositol trisphosphate receptors. *J Pharmacol Exp Ther* 2005; 314: 1386-1392.

73. Darling CE, Jiang R, Maynard M, Whittaker P, Vinten-Johansen J, **Przyklenk K.** 'Postconditioning' via stuttering reperfusion limits myocardial infarct size in rabbit hearts: role of ERK 1/2. *Am J Physiol* 2005; 289: H1618-H1626.

74. **Przyklenk K,** Maynard M, Whittaker P. Reduction of infarct size with D-*myo*-inositol trisphosphate: role of PI3-kinase and mitochondrial K_{ATP} channels. *Am J Physiol* 2006; 290: H830-H836.

75. Yuan C, Gou Y, Ravi R, **Przyklenk K**, Shilkofski N, Diez R, Cole RN, Murphy AM. Myosin binding protein C is differentially phosphorylated upon myocardial stunning in canine and rat hearts: evidence for novel phosphorylation sites. *Proteomics* 2006: 6: 4176-4186.

76. **Przyklenk K**, Maynard M, Whittaker P. First molecular evidence that inositol trisphosphate signaling contributes to infarct size reduction with preconditioning. *Am J Physiol* 2006: 291: H2008-2012.

77. Linden MD, Whittaker P, Frelinger AL III, Barnard M, Michelson AD, **Przyklenk K.** Preconditioning ischemia attenuates myocardial indices of platelet activation-aggregation. *J Thromb Haemostasis* 2006: 4: 2670-2677.

78. **Przyklenk K,** Whittaker P. Adaptation of a photochemical method to initiate recurrent platelet-mediated thrombosis in small animals. *Lasers Med Sci* 2006; 22: 42-45.

79. Darling CE, Solari PR, Smith CS, Furman MI, **Przyklenk K.** 'Postconditioning' the human heart: multiple balloon inflations during cardiac catheterization may confer cardioprotection. *Basic Res Cardiol* 2007; 102: 274-278.

80. Linden MD, Furman MI, Frelinger AL III, Fox ML, Barnard MR, Li Y, **Przyklenk K,** Michelson AD. Indices of platelet activation as markers of the acuity of coronary artery disease. *J Thromb Haemostasis* 2007; 5: 761-765.

81. Linden MD, Barnard MR, Frelinger AL, Michelson AD, **Przyklenk K.** Effect of adenosine A_2 receptor stimulation on platelet activation-aggregation: differences between canine and human models. *Thromb Res* 2008; 121: 689-698.

82. **Przyklenk K**, Maynard M, Darling CE, Whittaker P. Aging mouse hearts are refractory to infarct size reduction with postconditioning. *J Am Coll Cardiol* 2008; 51: 1393-1398.

83. Hüttemann M, Lee I, Pecinova A, Pecina P, Yu H, **Przyklenk K**, Doan JW. Regulation of oxidative phosphorylation, the mitochondrial membrane potential, and their role in human disease. *J Bioenergetics Biomembranes* 2008; 40: 445-456.

84. Whittaker P, **Przyklenk K.** Fibrin architecture in clots: a quantitative polarized light microscopy analysis. *Blood Cells Mol Dis*: 2009; 42: 51-56.

85. Darling CE, Michelson AD, Volturo GA, **Przyklenk K**. Platelet reactivity and the identification of acute coronary syndromes in the emergency department. *J Thromb Thrombolysis* 2009; 28: 31-37.

86. Cohen J, Goedecke E, Cyrkler JE, Mangolds VB, Bateman J, **Przyklenk K**, Mullen MT. Early glycemic control in critically ill emergency department patients: pilot trial. *West J Emerg Med* 2010; 11:20-23.

87. **Przyklenk K,** Frelinger AL III, Linden MD, Whittaker P. Li Y, Barnard MR. Adams J, Morgan M, Al-Shamma H, Michelson AD. Targeted inhibition of the serotonin 5-HT_{2A} receptor improves coronary patency in an *in vivo* model of recurrent thrombosis. *J Thromb Haemostasis*: 2010; 10: 331-340.

88. Pecina P, Borisenko GG, Belikova NA, Pecinova A, Lee I, Samhan-Arias AK, **Przyklenk K,** Kagan VE, Hüttemann M. Phosphomimetic substitution of cytochrome *c* tyrosine 48 decreases respiration and binding to cardiolipin, and abolishes ability to trigger downstream caspase activation. *Biochemistry* 2010: 49: 6705-14.

89. Dong Y, Undyala VV, Gottlieb RA, Mentzer RM Jr, **Przyklenk K.** Autophagy: definition, molecular machinery and potential role in myocardial ischemia-reperfusion injury. *J Cardiovasc Pharm Ther*: 2010; 15: 220-230.

90. Sala Mercado JA, Wider J, Undyala VV, Jahania S, Mentzer RM Jr, Gottlieb RA, **Przyklenk K.** Profound cardioprotection with chloramphenicol succinate in the swine model of myocardial ischemia-reperfusion injury. *Circulation* 2010; 122(Suppl I): S179-S184.

91. **Przyklenk K,** Maynard M, Grenier DL, Whittaker P. Cardioprotection with postconditioning: loss of efficacy in murine models of type-2 and type-1 diabetes. *Antioxid Redox Signal*: 2011; 14: 781-90.

92. **Przyklenk, K.** Efficacy of cardioprotective 'conditioning' strategies in aging and diabetic cohorts: the comorbidity conundrum. *Drugs & Aging* 2011; 28: 331-43.

93. Ehrman R, Wira C, Lomax A, Hayward A, Marcelin J, Ellis T, **Przyklenk K**, Volturo G, Mullen M. Etomidate use in severe sepsis and septic shock patients does not contribute to mortality. *Intern Emerg Med* 2011; 6: 253-57.

94. Schwartz Longacre L, Kloner RA, Arai AE, Baines CP, Bolli R, Braunwald E, Downey J, Gibbons RJ, Gottlieb RA, Heusch G, Jennings RB, Lefer DJ, Mentzer RM, Murphy E, Ovize M, Ping P, **Przyklenk K**, Sack MN, Vander Heide RS, Vinten-Johansen J, Yellon DM. New horizons in cardioprotection: recommendations from the 2010 National Heart, Lung and Blood Institute Workshop. *Circulation* 2011; 134:1172-79.

95. Whittaker P, **Przyklenk K.** Remote conditioning ischemia provides a potential approach to mitigate contrast media-induced reduction in kidney function: a retrospective case series. *Cardiology* 2011;119:145-50.

96. Ovize M, Thibault H, **Przyklenk K.** Myocardial conditioning: opportunities for clinical translation. *Circ Res* 2013; 113:439-50.

97. Darling CE, Sala-Mercado JA, Quiroga-Castro W, Tecco GF, Zelaya FR, Conci EC, Sala JP, Smith CS, Michelson AD, Whittaker P, Welch RD, **Przyklenk K.** Point-of-care assessment of platelet reactivity in the Emergency Department may facilitate rapid rule-out of acute coronary syndromes: a prospective cohort pilot feasibility study. *BMJ Open* 2014; 4:e003883.

98. Wider J, **Przyklenk K.** Ischemic conditioning: the challenge of protecting the diabetic heart. *Cardiovasc Diagn Ther* 2014; 4:383-96.

99. Heusch G, Botker HE, **Przyklenk K**, Redington AN, Yellon DM. State-of-the-art review: remote ischemic conditioning. *J Am Coll Cardiol* 2015; 65:177-95.

100. **Przyklenk K.** Ischemic 'conditioning': pitfalls on the path to clinical translation. *Br J Pharmacol* 2015; 172:1961-73.

101. Datta NS, Chukkapalli S, Vengalil N, Zhan E, **Przyklenk K,** Lasley RD. Parathyroid-related peptide protects cardiomyocytes from oxidative stress-induced cell death: first evidence of a novel endocrine-cardiovascular interaction. *Biochem Biophys Res Commun* 2015: 468:202-7.

102. ****** Gremmel T, Yanachkov IB, Yanachkova M, Wright GE, Wider J, Undyala VVR, Michelson AD, Frelinger AL III, **Przyklenk K.** Synergistic inhibition of both platelet adenosine diphosphate receptors as novel approach to attenuate pathophysiologic platelet aggregation. *Arterioscler Thromb Vasc Biol* 2016; 36: 501-509.

******* selected by ATVB as the best paper on thrombosis published in 2016, with TG awarded the 2017 Karl Link Early Career Investigator Award in Thrombosis*

103. Kumar R, Bukowski MJ, Wider JM, Reynolds CA, Calo L, Lepore B, Tousignant R, Jones M, **Przyklenk K,** Sanderson TH. Mitochondrial dynamics following global cerebral ischemia. *Mol Cell Neurosci* 2016; 76:68-75.

104. Dong Y, Undyala VVR, **Przyklenk K.** Inhibition of mitochondrial fission as a molecular target for cardioprotection: critical importance of the timing of treatment. *Basic Res Cardiol* 2016;111:59.

105. Pearson C, **Przyklenk K,** Mika V, Ayaz SI, Ellis M, Varade P, Tolomello R, Welch RD. Utility of point of care assessment of platelet reactivity (using the PFA-100®) to aid in diagnosis of stroke. *Am J Emergency Med* 2017;35:802.e1-802.e5.

106. Arnetz BB, Lewalski P, Arnetz J, Breejen K, **Przyklenk K.** Examining self-reported and biological stress and near misses among Emergency Medicine residents: a single centre cross-sectional assessment in the USA. *BMJ Open* 2017;7:e016479.

107. Sanderson TH, Wider J, Lee I, Reynolds CA, Liu J, Lepore B, Tousignant R, Bukowski MJ, Johnston H, Fite A, Raghunayakula S, Kamholz J, Grossman LI, **Przyklenk K,** Hüttemann M. Inhibitory modulation of cytochrome *c* oxidase activity with specific near-infrared light wavelengths attenuates brain ischemia/reperfusion injury. *Scientific Reports* 2018;8:3481.

108. Wider J, Undyala VVR, Whittaker P, Woods J, Chen X, **Przyklenk K**. Remote ischemic preconditioning fails to reduce infarct size in the Zucker Fatty Rat model of type-2 diabetes: role of defective humoral communication. *Basic Res Cardiol* 2018;113:16.

109. Koganov ES, Michelson AD, Yanachkov IB, Yanachkova MI, Wright GE, **Przyklenk K**, Frelinger AL III. GLS-409, an antagonist of both P2Y1 and P2Y12, potently inhibits canine coronary artery thrombosis and reversibly inhibits human platelet activation. *Scientific Reports* 2018;8:14529.

110. Strubakos CD, Malik M, Wider JM, Lee I, Reynolds CA, Mitsias P, **Przyklenk K**, Hüttemann M, Sanderson TH. Non-invasive treatment with near-infrared light: a novel mechanisms-based strategy that evokes sustained reduction in brain injury after stroke**.** *J Cereb Blood Flow Metab* 2020;40:833-44 .

111. Kulek AR, Anzell A, Wider JM, Sanderson TH, **Przyklenk K.** Mitochondrial quality control: role in cardiac models of lethal ischemia-reperfusion injury. *Cells* 2020: 9:214.

112. Knowles S, Cyrus A, Slavish DC, **Przyklenk K**, Arnetz B. Sleep, inflammation and telomere length in veterans. *Sleep Medicine* 2021: in revision.

113. Fogo G, Anzell AR, Maheras KJ, Raghunayakula S, Wider JM, Emaus K, Bryson T, Bukowski M, Neumar RW, **Przyklenk K**, Sanderson TH. Machine learning-based classification of mitochondrial morphology in primary neurons and brain. *Scientific Reports* 2021;11:5133..

114. Anzell AR, Fogo G, Gurm Z, Raghunayakula S, Wider JM, Maheras KJ, Emaus K, Bryson T, Wang M, Ganley I, Sesaki H, Neumar RW, **Przyklenk K**, Sanderson TH. Mitochondrial fission and mitophagy are independent mechanisms regulating ischemia-reperfusion injury in primary neurons. *Cell Death & Disease* 2021;12:475.

115. Krishnan AC, Sala-Mercado JA, O'Leary DS, Lovelace AT, **Przyklenk K,** Rossi NF, Jin JP, Lanfear DD, Maybaum SW, Levy PD. Development of a translational canine model of acute decompensated heart failure to test acute heart failure therapies. *Scientific Reports* 2021: in revision.

INVITED REVIEW ARTICLES:

1. **Przyklenk K,** Kloner RA. Free radicals: role in ischemia and infarction. *Cardio* November 1986: 54-58.

2. Campbell CA, **Przyklenk K,** Kloner RA. Infarct size reduction: a review of the clinical trials. J Clin *Pharmacol* 1986, 26: 317-329.

3. Kloner RA, **Przyklenk K,** Campbell CA. Coronary reperfusion following experimental myocardial infarction. *J Cardiac Surg* 1987, 2: 291-297.

4. Kloner RA, **Przyklenk K.** Recent advances in stunned myocardium. *Cardiovascular Reviews & Reports* 1987; 8: 25-29.

5. **Przyklenk K.** Oxygen-derived free radicals and stunned myocardium. *Free Radical Biol Med* 1988; 4: 39-44.

6. Patel B, Kloner RA, **Przyklenk K,** Braunwald E. Postischemic myocardial stunning: a clinically relevant phenomenon. *Ann Int Med* 1988; 108: 627-629.

7. Kloner RA, **Przyklenk K,** Patel B. Altered myocardial states: the stunned and hibernating myocardium. *Am J Med* 1988; 86 (Suppl A): 14-22.

8. Kloner RA, **Przyklenk K.** Coronary artery reperfusion for the treatment of acute myocardial infarction. *Internal Medicine for the Specialist* 1989; 10: 54-65.

9. **Przyklenk K,** Kloner RA. Stunned myocardium: characteristics and implications. *Cardio* April 1989: 130-134.

10. **Przyklenk K,** Kloner RA. What factors predict recovery of contractile function in the canine model of the stunned myocardium? *Am J Cardiol* 1989; 64: 18F-26F.

11. **Przyklenk K,** Kloner RA. Relationship between structure and effects of ACE inhibitors: comparative effects in myocardial ischemia/reperfusion injury. *British J Clin Pharmacol* 1989; 28: 167S-175S.

12. Kloner RA, **Przyklenk K.** Recent advances in stunned myocardium. [Original 1987 manuscript reprinted as part of the "Classics of the Decade Series", and update 1990]. *Cardiovascular Reviews & Reports* 1990; 11: 68-74.

13. Mehta PM, **Przyklenk K,** Kloner RA. Cardioprotective effect of captopril in myocardial ischemia, ischemia/reperfusion and infarction. *European Heart J* 1990; 11 (Suppl B): 94-99.

14. Kloner RA, **Przyklenk K.** Progress in cardioprotection: the role of the calcium antagonists. *Am J Cardiol* 1990; 66: 2H-9H.

15. Kloner RA, **Przyklenk K.** The stunned and hibernating myocardium. *Ann Review Med* 1991; 42: 1-8.

16. Kloner RA, **Przyklenk K.** Adjuvant therapy for coronary reperfusion: role of oxygen radical scavengers? *Western J Med* 1991; 154: 436-411.

17. **Przyklenk K,** Kloner RA. Calcium antagonists and the stunned myocardium: importance for clinicians? *Cardiovasc Drugs Therapy* 1991; 5: 947-952.

18. **Przyklenk K,** Kloner RA. Calcium antagonists and the stunned myocardium. *J Cardiovasc. Pharmacol* 1991; 18 (Suppl 10): S93-S101.

19. Ovize M, Li Y, **Przyklenk K,** Kloner RA. Evidence from experimental models for myocardial protection during ischemia. *Current Opinion in Cardiology* 1992; 7: 563-570.

20. **Przyklenk K**, Ovize M, Kloner RA. Transient postischemic contraction: a reliable indicator of viable myocardium? *Am J. Cardiac Imaging* 1992; 6: 259-266.

21. Kloner RA, **Przyklenk K.** Dysfunctional myocardium: "dead or alive"? *Am J Cardiac Imaging* 1992; 6: 197-199.

22. Kloner RA, **Przyklenk K.** Cardioprotection with angiotensin converting enzyme inhibitors: redefined for the 1990's. *Clin Cardiol* 1992; 15:95-103.

23. Kloner RA, **Przyklenk K.** Understanding the jargon: A glossary of terms used (and misused) in the study of ischemia and reperfusion. *Cardiovasc Res* 1993; 27: 162-166.

24. **Przyklenk K,** Ovize M, Bauer B, Kloner RA. Ischemic preconditioning: an endogenous cardioprotective phenomenon? *Journal of Myocardial Ischemia* 1993; 5: 13-24.

25. **Przyklenk K,** Kloner RA. "Cardioprotection" by ACE inhibitors in acute ischemia and infarction? *Basic Res Cardiol* 1993; 88 (Suppl I): 139-154.

26. Kloner RA, **Przyklenk K,** Kay GL. Clinical evidence for stunned myocardium after coronary artery bypass surgery. *J Cardiac Surg* 1994; 9: 397-402.

27. Kloner RA, **Przyklenk K,** Shook T, Matthews RV, Burstein S, Cannom DS, Kay GL. Clinical aspects of preconditioning and implications for the cardiac surgeon. *J Cardiac Surg* 1995: 10:369-375.

28. Kloner RA, **Przyklenk K**, Shook T. The role of preconditioning ischemia in the reduction of myocardial infarct size. *Editorials in Cardiology* 1995; 1: 67-71. [Translated into French: Le rôle du préconditionnement ischémique dans la diminution de la taille de l'infarctus. *L'Information Cardiologique* 1995; 19: 125-129.]

29. Birnbaum Y, **Przyklenk, K,** Kloner RA. The time frame of ischemic preconditioning: Is it clinically relevant? *J Cardiovasc Pharmacol Ther* 1996; 1: 39-346.

30. Schwarz ER, **Przyklenk K,** vom Dahl J, Schoendube FA, Hanrath P, Kloner RA. Chronic hibernating myocardium: concepts and controversies. *Congestive Heart Failure* May/June 1997: 12-23.

31. Kloner RA, Bolli R, Marban E, Reinlib L, Braunwald E and participants. Medical and cellular implications of stunning, hibernation and preconditioning: an NHLBI workshop. *Circulation* 1998; 97: 1848-1867.

32. **Przyklenk K,** Kloner RA. Ischemic preconditioning: exploring the paradox. *Prog Cardiovasc Diseases* 1998; 40: 517-547.

33. Simkhovich BZ, **Przyklenk K,** Kloner RA. Role of protein kinase C as a cellular mediator of ischemic preconditioning: a critical review. *Cardiovasc Res* 1998; 40: 9-22.

34. **Przyklenk K,** Simkhovich BZ, Bauer B, Hata K, Zhao L., Elliott GT, Kloner RA. Cellular mechanisms of infarct size reduction with preconditioning: role of calcium? *Ann NY Acad Sci* 1999; 874: 192-210.

35. **Przyklenk K.** Key references: Ischemic preconditioning. *J Thromb Thrombolysis* 2000; 9: 99-103.

36. Kloner RA, Shook T, Cannon CP, **Przyklenk K.** Ischemic preconditioning: implications for the geriatric heart. *Am J Geriatric Cardiol* 2001; 10: 145-148.

37. **Przyklenk K.** Pharmacologic treatment of the stunned myocardium: the concepts and the challenges. *Coronary Artery Dis* 2001; 12: 363-370.

38. Kloner RA, Speakman MT, Przyklenk K. Ischemic preconditioning: a plea for targeted clinical trials. *Cardiovasc Res* 2002; 55: 526-533.

39. **Przyklenk K,** Darling CE, Dickson EW, Whittaker P. Cardioprotection 'outside the box': the evolving paradigm of remote preconditioning. *Basic Res Cardiol* 2003: 98: 149-157.

40. **Przyklenk K,** Kukreja RC. Sildenafil citrate (Viagra) in experimental models of acute coronary syndromes. Print version: *Journal Salud (i) Ciencia* 2003. [On-line version: http://www.siicsalud.com/des/des032/03710007i.htm]

41. Linden MD, Frelinger AL III, Barnard MR, **Przyklenk K,** Furman MI, Michelson AD. Application of flow cytometry to platelet disorders. *Seminars Thromb Hemostasis* 2004; 5: 501-511.

42. Volturo GA, Mazzola JL, **Przyklenk K.** The role of antiplatelet therapy in the management of acute coronary syndromes. *Expert Opin Drug Safety* 2005; 4:541-556.

43. **Przyklenk K.** Design of novel strategies to limit heart damage in the setting of acute myocardial infarction. *Business Briefings: Emergency Medicine Review* 2005 (June): 62-64.

44. Darling CE, **Przyklenk K.** 'Postconditioning': A new paradigm for myocardial protection? *Current Reviews in Cardiology* 2005; 1: 195-201.

45. Linden MD, Frelinger AL III, **Przyklenk K**, Furman MI, Michelson AD. Aspirin resistance: detection, mechanisms and clinical implications. *Current Reviews in Cardiology* 2005; 1: 203-211.

46. **Przyklenk K**, Darling CE, Volutro GA, Michelson AD. On-site assessment of platelet reactivity in the emergency department. *Touch Briefings' Emergency Medicine and Critical Care Review* December 2006: 28-30.

47. Young KD on behalf of the 2005-2006 and 2006-2007 Society for Academic Emergency Medicine Grants Committees. Productivity and career paths of previous recipients of Society for Academic Emergency Medicine research grant awards. *Acad Emerg Med* 2008; 15: 560-566.

48. Vinten-Johansen J, Granfeldt A, Mykytenko J, Undyala VV, Dong Y, **Przyklenk K.** The multi-dimensional physiological responses to postconditioning. *Antioxid Redox Signal* 2011: 14; 791-810.
49. **Przyklenk K**, Whittaker P. Remote ischemic preconditioning: current knowledge, unresolved questions and future priorities. *J Cardiovasc Pharm Ther* 2011: 16; 255-259.

50. **Przyklenk K,** Dong Y, Undyala VVR, Whittaker P. Autophagy as a therapeutic target for ischemia-reperfusion injury? Concepts, controversies and challenges. *Cardiovasc Res* 2012; 94; 197-205.

51. Klionsky DJ *et al* (total of 1042 authors [alphabetical list], including **Przyklenk K**). Guidelines for the use and interpretation of assays for monitoring autophagy. *Autophagy* 2012; 8: 455-544.

52. Sanderson TH, Reynolds CA, Kumar R, **Przyklenk K,** Hüttemann M. Molecular mechanisms of ischemia-reperfusion injury in brain: pivotal role of the mitochondrial membrane potential in reactive oxygen species generation. *Molecular Neurobiology* 2013;47:9-23.

53. Reynolds CA, Hüttemann M, **Przyklenk K**, Sanderson TH. Hypoxia-induced damage to the adult and immature brain: molecular mechanism of oxidative damage and the need for targeted therapeutic intervention. *Hypoxia: Causes, Types and Management*. 2013:346:7-10.

54. **Przyklenk K**, Whittaker P. Genesis of remote conditioning. Action at a distance: *'hypotheses non fingo'*? *J Cardiovasc Med* 2013;14:179-85.

55. **Przyklenk K.** Reduction of myocardial infarct size with ischemic 'conditioning': physiologic and technical considerations. *Anesthesia & Analgesia* 2013; 117:891-901.

56. Calo L, Dong Y, Kumar R, **Przyklenk K,** Sanderson TH. Mitochondrial dynamics: an emerging paradigm in ischemia-reperfusion injury. *Current Pharmaceutical Design* 2013;19:6848-57.

57. Simkhovich BZ, **Przyklenk K,** Kloner RA. Role of protein kinase C in ischemic 'conditioning': from first evidence to current perspectives. *J Cardiovasc Pharm Ther* 2013;18:525-32.

58. Whittaker P, **Przyklenk K.** From ischemic conditioning to 'hyperconditioning': clinical phenomenon and basic science opportunity? *Dose Response* 2014;12:650-663.

59. Klionsky DJ *et al* (total of 2035 authors [alphabetical list], including **Przyklenk K**). Guidelines for the use and interpretation of assays for monitoring autophagy: 3rd Edition. *Autophagy* 2016;12:1-222.

60. Hausenloy DJ, Barrabes JA, Bøtker HE, Davidson SM, Di Lisa F, Downey J, Engstrom T, Ferdinandy P, Carbrera-Fuentes H, Heusch G, Ibanez B, Iliodromitis EK, Inserte J, Jennings R, Kalia N, Kharbanda RK, Lecour S, Marber M, Miura T, Ovize M, Perez-Pinzon MA, Piper HM, **Przyklenk K**, Schmidt MR, Redington A, Ruiz-Meana M, Vilahur G, Vinten-Johansen J, Yellon DM, Garcia-Dorado M. Ischaemic conditioning and targeting reperfusion: a 30 year voyage of discovery. *Basic Res Cardiol* 2016;111:70.

61. Datta T, **Przyklenk K,** Datta NS. Parathyroid hormone-related peptide (PTHrP): a novel endocrine cardioprotective 'conditioning' mimetic? *J Cardiovasc Pharm Ther* 2017;22:529-37.

62. **Przyklenk K,** Whittaker P. Ischemic conditioning attenuates platelet-mediated thrombosis: a tale of reverse translation. *J Cardiovasc Pharm Ther* 2017;22:391-96.

63. Anzell AR, Maizy R, **Przyklenk K,** Sanderson TH. Mitochondrial quality control and disease: insights into ischemia-reperfusion injury. *Molecular Neurobiology* 2018;55:2547-64.

64. Lindsey ML. Bolli R, Canty J, Du XJ, Frangogiannis NG, Frantz S, Gourdie R, Holmes JW, Jones SP, Kloner RA, Lefer DJ, Liao R, Murphy E, Ping P, **Przyklenk K,** Recchia F, Schwartz Longacre L, Ripplinger CM, Van Eyk J, Heusch G. Guidelines for animal models of myocardial ischemia and infarction. *Am J Physiol* 2018;314:H812-38.
Podcast: http://ajpheart.podbean.com posted March 23, 2018.

Selected by The American Journal of Physiology – Heart and Circulatory Physiology to receive the 'Best Paper Award 2018: Review Article'

65. Sprick JD, Mallet RT, **Przyklenk K**, Rickards CA. Ischemic and hypoxic conditioning: potential for protection of vital organs. *Exp Physiol* 2019;104:278-94.

66. Wider JM, **Przyklenk K.** Ischemic conditioning: the diabetes dilemma. *Conditioning Medicine* 2019;2:10-17.

EDITORIALS AND INVITED COMMENTARIES:

1. Kloner RA, **Przyklenk K.** Experimental infarct size reduction with calcium channel blockers. *J Am Coll Cardiol* 1991; 18: 876-878.

2. Kloner RA, **Przyklenk K.** Hibernation and stunning of the myocardium. *N Engl J Med* 1991; 325: 1877-1879.

3. **Przyklenk K,** Kloner RA. Calcium antagonists and the stunned myocardium: A role during ischemia? A role during reperfusion? *Cardiovasc Res* 1992; 26: 82-84.

4. Kloner RA, **Przyklenk K,** Whittaker P, Hale SL. Preconditioning-like phenomena and inadvertent preconditioning. *J Mol Cell Cardiol* 1995; 27: 743-747.

5. **Przyklenk K,** Kloner RA. Preconditioning: A balanced perspective. *British Heart J* 1995; 74: 575-577.

6. **Przyklenk, K.** Oxygen radical scavengers as adjuvant therapy for coronary reperfusion. *J Thromb Thrombolysis* 1996; 3: 35-40.

7. **Przyklenk K,** Kloner RA. Role of protein kinase C in ischemic preconditioning: In search of the "pure and simple truth". *Basic Res Cardiol* 1996; 91: 41-43 and New Paradigms of Coronary Artery Disease: Stunning, Hibernating and Ischemic Preconditioning (G. Heusch and R. Schulz, Eds) Steinkopff, Darmstadt, 1996, p 159-161.

8. **Przyklenk K.** Lethal myocardial "reperfusion injury": The opinions of good men. *J Thromb Thrombolysis* 1997; 4: 5-6.

9. Kloner RA, **Przyklenk K.** Clinical evidence that nisoldipine attenuates stunning in patients post-infarction. *Cardiovasc Drugs Therapy* 1997; 11: 17-18.

10. **Przyklenk K,** Hutsell TC, Hata K, Whittaker P. Targeted coronary thrombolysis via "pericardial" administration of lytic agents? *J Thromb Thrombolysis* 1998; 6: 83-88.

11. **Przyklenk K.** Cardioprotection with sodium-hydrogen exchange inhibition: an archetype of "bench to bedside". *J Thromb Thrombolysis* 1999; 8: 5.

12. **Przyklenk K,** Heusch G. Late preconditioning against myocardial stunning: does aspirin close the 'second window' of endogenous cardioprotection? *J Am Coll Cardiol* 2003: 41: 1195-1197.

13. **Przyklenk K,** Whittaker P. Cardioprotection with adenosine: 'a riddle wrapped in a mystery'. *British J Pharmacol* 2005; 145; 699-700.

14. **Przyklenk K.** Reduction of infarct size with 'postconditioning': the concept of modified reperfusion. *Federaćion Argentina de Cardiologia - 6th Virtual Congress of Cardiology* 2009: http://www.fac.org.ar/6cvc/llave/c162/przyklenkk.php

15. **Przyklenk K,** Undyala VVR, Wider J, Sala-Mercado JA, Gottlieb RA, Mentzer RM Jr. Acute induction of autophagy as a novel strategy for cardioprotection: getting to the heart of the matter. *Autophagy* 2011; 7: 432-433.

16. **Przyklenk K,** Whittaker P. Cardioprotection via adaptation to hypoxia: expanding the timeline and targets? *Basic Res Cardiol* 2011; 106: 325-328.

17. **Przyklenk K.** Role of adenosine A_{2B} receptor stimulation in ischemic preconditioning: dawn of a new paradigm in cardioprotection. *Cardiovasc Res* 2012; 96: 195-197.

18. **Przyklenk K.** 'Going out on a limb': SDF-1α/CXCR4 signaling as a mechanism of remote ischemic preconditioning? *Basic Res Cardiol* 2013; 108; 302.

19. **Przyklenk K**, Sanderson TH, Hüttemann M. Clinical benefits of remote ischemic preconditioning: new insights . . . and new questions. *Circ Res* 2014; 114:748-750.

20. **Przyklenk K.** Role of extracellular vesicles in remote ischemic preconditioning: 'good things come in small packages'? *J Mol Cell Cardiol* 2014: 69:83-84.

21. **Przyklenk K.** microRNA-144: the 'what' and 'how' of remote ischemic conditioning? *Basic Res Cardiol* 2014; 109:429.

22. Garratt KN, Whittaker P, **Przyklenk K.** Remote ischemic conditioning and the long road to clinical translation: lessons learned from ERICCA and RIPHeart. *Circ Res* 2016; 18:1052-54.

23. **Przyklenk K,** Whittaker P. The future of remote ischemic conditioning: new perspectives after ERICCA and RIPHeart. *J Cardiovasc Pharm Ther* 2017; 22:295-296.

24. **Przyklenk K.** Journal of Cardiovascular Pharmacology and Therapeutics: Expanding the legacy. *J Cardiovasc Pharm Ther* 2019; 24:303.

BOOK CHAPTERS AND MONOGRAPHS:

1. Kloner RA, **Przyklenk K**, Lange R, Ellis SG. Reperfusion pathophysiology. In: Myocardial Protection in Cardiac Surgery (A.J. Roberts, Ed.) Marcel-Dekker, Inc., New York, 1987, p 29-52.

2. **Przyklenk K,** Kloner RA. Acute effects of antioxidants in experimental myocardial ischemia and infarction. In: Free Radicals in the Pathophysiology of Heart Disease (P.K. Singal, Ed.) Martinus Nijoff Publishing Co., Boston, 1988, p 227-237.

3. **Przyklenk K.** Effect of ACE inhibition of acute myocardial ischemia/reperfusion injury. In: Cardioprotection by Converting Enzyme Inhibition: Highlights of Satellite Symposium No. 9 of the 12th International Society of Hypertension (R.M. Zusman, Ed.) Excerpta Medica, Princeton, 1988, p 28-33.

4. **Przyklenk K**, Whittaker P, Kloner RA. Zofenopril, a newly developed sulfhydryl-containing angiotensin converting enzyme inhibitor, enhances contractile function of stunned myocardium. In: Current Advances in ACE Inhibition (G.A. MacGregor and P.S. Sever, Eds.) Churchill Livingstone, London, 1989, p 279-282.

5. Kloner RA, **Przyklenk K**, Rahimtoola SH, Braunwald E. Myocardial stunning and hibernation: mechanisms and clinical implications. In: Heart Disease: A Textbook of Cardiovascular Medicine (3rd Edition): Update 11 (E. Braunwald, Ed.) W.B. Saunders Co., New York, 1991, p 241-256.

6. Kloner RA, **Przyklenk K.** Consequences of ischemia/reperfusion on the coronary microvasculature. In: Myocardial Protection: The Pathophysiology of Reperfusion and Reperfusion Injury (D. Yellon and R.B. Jennings, Ed.) Raven Press, New York, 1992, p 85-103.

7. Kloner RA, **Przyklenk, K.** Reperfusion injury to the heart: Is it a real phenomenon? In: Cardiovascular Toxicology (2nd Edition) (D. Acosta, Ed.) Raven Press, New York, 1992, p 131-140.

8. **Przyklenk K,** Kloner RA. Calcium antagonists and the stunned myocardium: importance for clinicians? In: Stunning, Hibernation and Calcium in Myocardial Ischemia and Reperfusion (L. Opie, Ed.) Kluwer Academic Publishers, Boston MA, 1992, p 180-189.

9. Kloner RA, **Przyklenk K,** Rahimtoola SH, Braunwald E. Myocardial stunning and hibernation: mechanisms and clinical implications. In: Stunning, Hibernation and Calcium in Myocardial Ischemia and Reperfusion (L. Opie, Ed.) Kluwer Academic Publishers, Boston MA, 1992, p 251-280.

10. Kloner RA, **Przyklenk K.** "First evidence": postischemic dysfunction of viable myocardium and associated abnormalities. In: Stunned Myocardium: Properties, Mechanisms, and Clinical Manifestations (R.A. Kloner and **K. Przyklenk,** Eds.) Marcel-Dekker Inc., New York, 1993, p 17-40.

11. **Przyklenk K**, Apstein CS. Stunned myocardium in the isolated perfused heart preparation. In: Stunned Myocardium: Properties, Mechanisms, and Clinical Manifestations (R.A. Kloner and **K. Przyklenk,** Eds.) Marcel-Dekker Inc., New York, 1993, 109-130.

12. **Przyklenk K,** Whittaker P. Other theories: myths, fads or facts? n: Stunned Myocardium: Properties, Mechanisms, and Clinical Manifestations (R.A. Kloner and **K. Przyklenk,** Eds.) Marcel-Dekker Inc., New York, 1993, p 233-248.

13. **Przyklenk K,** Kloner RA. Calcium antagonists as "treatment" for the stunned myocardium. In: Stunned Myocardium: Properties, Mechanisms, and Clinical Manifestations (R.A. Kloner and **K. Przyklenk,** Eds.) Marcel-Dekker Inc., New York, 1993, p 281-302.

14. **Przyklenk K.** Angiotensin converting enzyme inhibitors. In: Stunned Myocardium: Properties, Mechanisms, and Clinical Manifestations (R.A. Kloner and **K. Przyklenk,** Eds.) Marcel-Dekker Inc., New York, 1993, p 321-336.

15. Ovize M, **Przyklenk K,** Kloner RA. Pathophysiology of acute coronary ischemia and reperfusion. In: Current Therapy for Acute Coronary Ischemia (H.L. Lazar, Ed.) Futura Publishing Co., New York, 1993, p 1-32.

16. **Przyklenk K,** Kloner RA. Diagnosis of stunned and hibernating myocardium. In: Cura Intensiva Cardiologica 1993 (G. Caturelli, Ed.) MGA s.r.l., Rome, 1994, p 36-44.

17. Ovize M, Kloner RA, **Przyklenk K.** Preconditioning and myocardial contractile function. In: Ischemic Preconditioning: The Concept of Endogenous Cardioprotection (**K. Przyklenk,** R.A. Kloner, and D. M. Yellon, Eds.) Kluwer Academic Publishers, Norwell MA, 1994, p 41-60.

18. Bauer B, Kloner RA, **Przyklenk K.** Preconditioning and the coronary vasculature. In: Ischemic Preconditioning: The Concept of Endogenous Cardioprotection (**K. Przyklenk,** R.A. Kloner, and D. M. Yellon, Eds.) Kluwer Academic Publishers, Norwell MA, 1994, p 61-72.

19. **Przyklenk K,** Kloner RA, Whittaker P. Synopsis of ischemic preconditioning: What have we learned since 1986? In: Ischemic Preconditioning: The Concept of Endogenous Cardioprotection (**K. Przyklenk,** R.A. Kloner, and D. M. Yellon, Eds.) Kluwer Academic Publishers, Norwell MA, 1994, 153-170.

20. Kloner RA, **Przyklenk K.** Is preconditioning relevant to clinical medicine? In: Ischemic Preconditioning: The Concept of Endogenous Cardioprotection (**K. Przyklenk,** R.A. Kloner, and D. M. Yellon, Eds.) Kluwer Academic Publishers, Norwell MA, 1994, p 173-187.

21. **Przyklenk K,** Kloner RA. Stunned and hibernating myocardium. In: New Types of Cardiovascular Diseases (J. Willis Hurst, Ed.) Igaku-Shoin Publishers, Inc., New York, 1994, p 24-45.

22. **Przyklenk K,** Kloner RA. Prevention of lethal myocardial "reperfusion injury": a clinically relevant phenomenon? Monograph: Topics in Preventive Cardiology (4/94) Excerpta Medica, Amsterdam, 1994.

23. Przyklenk K, Whittaker P, Ovize M, and Kloner RA. Reduction of infarct size with preconditioning: "Preconditioning at a distance". In: Myocardial Preconditioning (C.L. Wainwright and J. Parratt, Eds) R.G. Landes Co., Austin TX, 1996, p 79-96.

24. **Przyklenk K,** Kloner RA, Whittaker P. Increased perfusion via laser-mediated myocardial channels? Importance of appropriate models and endpoints. In: Direct Myocardial Revascularization: History, Methodology, Technology (P. Whittaker and G.S. Abela, Eds) Kluwer Academic Publishers, Norwell MA, 1999, p 61-80.

25. **Przyklenk K.** Mechanisms of acute cardioprotection with ischemic preconditioning: protein kinase C and beyond. In: Heart Failure: Frontiers in Cardiology (A. Kitabatake, S. Sasayama and G. S. Francis, Eds) Springer-Verlag, Tokyo Japan, 2000, p. 71-79.

26. Darling CE, **Przyklenk K.** Endogenous cardioprotection: a fresh look. In: Recent Developments in Physiology: Volume 2 (Part II) (SG Pandalai, Ed) Research Signpost, Kerala India, 2004, p. 385-401.

27. Ovize M, **Przyklenk K**. Mechanical versus ischemic preconditioning. In: Cardiac Mechano-Electric Feedback and Arrhythmias: From Pipette to Patient (P. Kohl, M. Franz and F. Sachs, Eds) Elsevier, Philadelphia PA, 2005, p. 164 – 170.

28. Mentzer, RM Jr., Gottlieb RA, **Przyklenk K,** Jahania MS. Myocardial protection. In: Cardiac Surgery in the Adult (4th Edition) (L.H. Cohn, Ed) ; McGraw Hill, New York NY, 2012, p. 355 – 379.

BOOKS:

1. Stunned Myocardium: Properties, Mechanisms and Clinical Manifestations (R.A. Kloner and **K. Przyklenk**, Eds.)Marcel-Dekker, New York, 1993.

2. Ischemic Preconditioning: The Concept of Endogenous Cardioprotection (**K. Przyklenk,** R.A. Kloner, and D. M. Yellon, Eds.) Kluwer Academic Publishers, Norwell MA, 1994.

INVITED LECTURES:

1. *Oxygen-derived free radicals and stunned myocardium.* Symposium on the Role of Free Radicals in Myocardial Ischemia and Infarction: Washington DC, March 1987.

2. *The stunned myocardium: role of oxygen-derived free radicals.* International Symposium on Free Radicals in Health and Disease: Winnipeg Canada, October 1987.

3. *Effect of angiotensin converting enzyme (ACE) inhibition on myocardial ischemia/reperfusion injury.* Satellite Symposium of the 12th Scientific Meeting of the International Society of Hypertension: Kyoto Japan, May 1988.

4. *Free radicals and reperfusion-induced myocardial injury.* Evolving Concepts in Clinical Cardiology: Boston MA, August 1988.

5. *The relationship between structure and effects of angiotensin converting enzyme inhibitors: comparative effects in myocardial ischemia/reperfusion.* International Symposium on ACE Inhibition: London UK, February 1989.

6. *Effects of ACE inhibitors on myocardial ischemia/reperfusion injury.* Satellite Symposium of the 11th Meeting of the Portuguese Congress of Cardiology: Madeira Portugal, April 1989.

7. *Reperfusion-induced myocardial injury and free radicals.* New Aspects of Drug Therapy in Ischemic Heart Disease: Würzburg Germany, June 1989.

8. *Effect of oxygen free radicals on myocardial systolic and diastolic function.* Current and Future Research Directions: Cardiology 1990: Los Angeles CA, May 1990.

9. *Calcium antagonists and the stunned myocardium.* Second International Symposium on Calcium Antagonists in Cardiovascular Care: Basel Switzerland, February 1991.

10. *Stunned and hibernating myocardium.* Workshop on ventricular function recovery following myocardial infarction in the thrombolytic era. Banff Canada, May 1991.

11. *Protection of the myocardium after infarction.* USC Cardiology 1991 Update: Puerto Vallarta Mexico, November 1991.

12. *Pathophysiology of myocardial ischemia/reperfusion injury.* 12th Myron B. Laver International Postgraduate Course in Anesthesiology: Perioperative Myocardial Ischemia: Basel Switzerland, March 1992.

13. *Antioxidants and free radical scavengers in experimental myocardial ischemia/reperfusion: effects of contractile function and the coronary vasculature.* Council on Myocardial Ischemia: Advisory Group Meeting on Coronary Atherogenesis: New York NY, September 1992.

14. I*nternational Workshop on Ischemic Preconditioning, Myocardial Stunning and Hibernation.* Hanbury Manor UK: October 1992.

15. *"Cardioprotection" by ACE inhibitors in acute myocardial ischemia and infarction?* International Symposium on Angiotensin and the Heart: Hamburg Germany, October 1992.

16. *Stunned and hibernating myocardium – Current Issues in Ischemia Reperfusion Injury.* Satellite Symposium of the 58th International Scientific Assembly of the American College of Chest Physicians: Chicago IL, October 1992.

17. *Diagnosis of stunned and hibernating myocardium*. IV International Symposium on Cardiological Intensive Care: Venice Italy, May 1993.

18. *Stunned myocardium: definition and evidence from the experimental laboratory.* Frontiers in Perioperative Myocardial Stunning: San Diego CA, September 1993.

19. *Stunned and hibernating myocardium.* Current Problems in Ischemic Heart Disease – International School of Cardiology: Erice Italy, September 1993.

20. *Effect of preconditioning on myocyte and endothelial function.* The Preconditioning Phenomenon – Postgraduate Course, 66th Annual Scientific Sessions of the American Heart Association: Atlanta GA, November 1993.

21. *Stunned myocardium: relationship with preconditioning.* Intrinsic Adaptive Mechanisms During Ischemia and Reperfusion: Nice France, October 1994.

22. *Pharmacologic modulation of ischemia and reperfusion: ACE inhibitors.* Intrinsic Adaptive Mechanisms During Ischemia and Reperfusion: Nice France, October 1994.

23. *Stunned and hibernating myocardium.* Visiting Professor, Hopital Cardiologique Louis Pradel: Lyon France, October 1994.

24. *Ischemic preconditioning: definition, properties and therapeutic implications.* Frontiers in Perioperative Myocardial Management: Montreal Canada, October 1994.

25. *Effect of preconditioning on cardiac function.* Preconditioning Symposium, 44th Annual Scientific Sessions of the American College of Cardiology: New Orleans LA. March 1995.

26. *Myocardial ischemia/reperfusion injury in the canine model.* Visiting Professor/Consultant, Searle Pharmaceuticals: St. Louis, MO. June 1995.

27. *Stunned and hibernating myocardium.* New Syndromes and Phenomena in Cardiovascular Disease: Los Angeles, CA. October 1995.

28. *Cardioprotection with ischemic preconditioning and monophosphoryl lipid A: What are the cellular mediators?* Visiting Professor/Consultant, RIBI Immunochem Research, Inc: Hamilton, MT. October 1995.

29. *Cellular mediators of preconditioning: The PKC controversy, role of 5' nucleotidase and calcium.* NHLBI Workshop: Medical and Cellular Implications of Stunning, Hibernation and Preconditioning: Columbia, MD. July 1996.

30. *Cardioprotection with ischemic preconditioning:* Definition, properties and therapeutic implications. Invited lecture, Harbor-UCLA Medical Center: Torrance CA. October 1996.

31. *Cardioprotection with ischemic preconditioning: Definition, properties and clinical implications.* Distinguished Scientist Lecture, Department of Physiology, University of South Alabama: Mobile, AL. September 1997.

32. *How to design an animal protocol to examine TMR.* Invited lecture at the symposium “Transmural myocardial laser revascularization (TMR)” Photonics West: San Jose, CA. January 1998.

33. *Cardioprotection with ischemic preconditioning: Definition, cellular mechanisms and clinical implications.* “Heart in Stress – III International Congress of Pathophysiology: Lahti, Finland June 1998.

34. *Cardioprotection with RIBI compounds in canine models of angina and infarction.* Visiting Professor/Consultant, RIBI Immunochem Research, Inc: Hamilton, MT. July 1998.

35. *Cardioprotection with ischemic preconditioning: Definition, cellular mechanisms and clinical implications.* Visiting Professor, School of Pharmacy, University of Montana: Missoula, MT. July 1998.

36. *Calcium and cardioprotection with ischemic preconditioning: role of sodium-hydrogen exchange.* Symposium: "Role of intracellular pH and the sodium-hydrogen exchanger in cardiac physiology and the response of the heart to ischemia and reperfusion" XX Annual Meeting of the American Section of the International Society for Heart Research: Ann Arbor, MI. August 1998.

37. *Cellular mechanisms and signal transduction pathways in ischemic preconditioning.* Symposium: "The late phase (second window) of ischemic preconditioning" XX Annual Meeting of the American Section of the International Society for Heart Research: Ann Arbor, MI. August 1998.

38. *Mechanisms of cardioprotection with ischemic preconditioning.* Special lecture: 2nd Annual Scientific Meeting of the Japanese Heart Failure Society: Sapporo, Japan October 1998.

39. *Novel strategies for protecting the ischemic heart: "Preconditioning with ischemia".* Invited lecture: Division of Cardiovascular Disease and Critical Care Medicine, Rush-Presbyterian-St. Luke's Medical Center: Chicago, IL. March 2000

40. *Cardioprotection with ischemic preconditioning: The "basics" . . . and beyond.* Visiting Professor/Consultant, Guilford Pharmaceuticals: Baltimore, MD. May 2000

41. *Cardioprotection with ischemic preconditioning: concepts and controversies.* Grand Rounds: University of Massachusetts Medical Center: Worcester, MA. September 2000

42. *Novel strategies for cardioprotection: "Preconditioning with ischemia"*. Invited lecture: Division of Cardiology, St. John Hospital and Medical Center: Detroit, MI. June 2001

43. *Treatment of stable angina: pharmacological approaches to chronic protection.* NIH/NHLBI Working Group on the Translation of Therapies for Protecting the Heart from Ischemia. National Institutes of Health: Bethesda MD. June 2003.

44. *Brief ischemia attenuates platelet-mediated thrombosis: expanding the paradigm of preconditioning.* XXV Annual Meeting of the American Section of the International Society for Heart Research: Mystic, CT. June 2003.

45. *Cardioprotection with ischemic preconditioning: basic science and clinical implications.* 51st Annual Meeting of the Japanese Society of Anesthesiology: Nagoya, Japan. May 2004.

46. *Mechanisms of preconditioning-induced cardioprotection: controversies and new concepts.* Visiting Professor, International Medical Exchange Seminar, Sapporo Medical University: Sapporo, Japan. June 2004.

47. *Brief antecedent ischemia attenuates platelet-mediated thrombosis: expanding the paradigm of preconditioning.* Visiting Professor, Sapporo Seminar for Cardiologists and Cardiac Surgeons: Sapporo, Japan. June 2004.

48. *Cardioprotection with ischemic preconditioning: controversies and new concepts.* Visiting Professor – Cardiovascular Research Seminar, University of Iowa: Iowa City, IA. November 2004.

49. *Cardioprotection with ischemic preconditioning: is efficacy maintained in aging cohorts?* 12th World Congress on Heart Disease: Vancouver, Canada. July 2005.

50. *New paradigms for cardioprotection: preconditioning, postconditioning . . . and beyond.* Visiting Professor: Robert M. Berne Cardiovascular Research Center, University of Virginia: Charlottesville, VA. September 2006.

51. *New paradigms for cardioprotection: preconditioning, postconditioning . . . and beyond.* Visiting Professor and Dean's Lecture: Interdisciplinary and Translational Seminar Series, Wayne State University: Detroit MI, April 2007.

52. *Limiting myocardial ischemia-reperfusion injury.* 13th World Congress on Heart Disease: Vancouver, Canada July 2007.

53. *Getting to the 'heart' of the matter: myocardial ischemia-reperfusion injury in models of type-2 and type-1 diabetes.* Endocrine Grand Rounds, Wayne State University, Detroit MI. May 2008

54. *Myocardial ischemia-reperfusion injury in the diabetic heart.* 14th World Congress on Heart Disease: Toronto, Canada July 2008.

55. *New paradigms for cardioprotection.* Visiting Professor: Columbia University Medical Center, New York, NY. March 2009.

56. *New strategies to improve outcome following 'heart attack': from mice to men.* Visiting Professor, Instituto Modelo de Cardiologia, Cordoba, Argentina April 2009.

57. *'Early point-of-care measurement of platelet reactivity: implications for rapid identification of acute coronary syndromes in the emergency department.* Visiting Professor, Instituto Modelo de Cardiologia, Cordoba, Argentina April 2009.

58. *New strategies to improve outcome following 'heart attack': from mice to men.* Visiting Professor, Department of Chemistry and Biochemistry, University of Windsor, Canada April 2009.

59. *New strategies to improve outcome following 'heart attack': from mice to men.* Visiting Professor, Department of Integrative Physiology, University of North Texas Health Sciences Center, Ft. Worth TX September 2009.

60. *Brief ischemia attenuates platelet-mediated thrombosis: expanding the paradigm of preconditioning.* Invited lecture at the Cardiovascular Seminar "The Impact of Ischemia-Reperfusion on Vascular Function", 2009 Scientific Sessions of the American Heart Association, Orlando FL November 2009.

61. *First evidence of remote ischemic preconditioning.* Invited lecture at the Satellite Symposium "Ischemic preconditioning: the time has come to harness its cardioprotective powers in patients, 2009 Scientific Sessions of the American Heart Association, Orlando FL November 2009.

62. *Cardioprotection in aging and diabetic cohorts.* Invited lecture at the symposium "Influence of major cardiovascular risk factors on cardioprotective mechanisms", XX World Congress of the International Society for Heart Research, Kyoto Japan, May 2010.

63. *Overview of physiology research: from molecules to mice to man.* Invited lecture, First Annual Wayne State University – University of Michigan Joint Physiology Symposium, Detroit MI, August 2010.

64. *Remote ischemic preconditioning.* NIH/NHLBI Workshop: New Horizons in Cardioprotection. National Institutes of Health, Bethesda MD, September 2010.

65. *Reduction of infarct size with postconditoning: from molecules to mice to man.* 9th International Congress on Coronary Artery Disease, Venice Italy, October 2011.

66. *Cardioprotection in diabetic and aging cohorts: getting to the 'heart' of the matter.* 75th Anniversary of Albert Szent-Györgyi's Nobel Prize Award, Szeged Hungary, March 2012

67. *Ischemic 'conditioning': physiologic and technical considerations.* International Symposium on Monitoring Perfusion, Oxygenation and Ventilation (IAMPOV), Yale University, New Haven CT, June 2012.

68. *Remote conditioning: poised for clinical translation?* The Cardioprotection Colloquium, UCLA, Los Angeles CA, November 2012.

69. *Myocardial ischemia-reperfusion injury: from basic principles to new paradigms*. Distinguished Lecturer, Institute of Biosciences and Technology, Texas A&M Health Science Center, Houston TX, April 2013.

70. *Remote ischemic conditioning: update on mechanisms.* ICT Inc. Focus Group Meeting: Ischemic Conditioning and Endothelial Function - From Research Studies to Patient Care, Dallas TX, November 2013.

71. *Remote ischemic 'conditioning': from inspiration . . . to clinical translation*. Adaptive Responses in Biology and Medicine: the 13th Annual Meeting of the International Dose-Response Society, University of Massachusetts Amherst, Amherst MA, April 2014.

72. *Myocardial ischemia-reperfusion injury: from basic principles to new paradigms*. Visiting Professor, Department of Physiology and Cell Biology, The Ohio State University, Columbus OH, May 2014.

73. *Myocardial ischemia, infarction and remodeling: can regenerative strategies mend broken hearts?* Wayne State University Department of Biomedical Engineering's 75th Anniversary Symposium, Detroit MI, August 2014.

74. *Cardioprotection with ischemic conditioning: the comorbidity conundrum.* Preconditioning in Biology and Medicine – Mechanisms and Translational Research: the 14th Annual Meeting of the International Dose-Response Society, University of Massachusetts Amherst, Amherst MA, April 2015.

75. Invited Discussant: *Does cyclosporine improve clinical outcomes in STEMI patients? The CIRCUS Trial.* European Society of Cardiology Congress (Session: Hot Line I – Acute Myocardial Infarction), London UK, August 2015.

76. *Myocardial ischemia-reperfusion injury: from basic principles to new paradigms*. Visiting Professor, Kosair Children's Hospital Research Institute and Department of Pediatrics, University of Louisville, Louisville KY, September 2015.

77. *Myocardial ischemia-reperfusion injury: from basic principles to new paradigms*. Visiting Professor, Cardiovascular Research Center, Massachusetts General Hospital, Boston MA, September 2015.

78. *Update on remote ischemic conditioning: basic and translational perspectives.* ICT Inc., Educational Webinar: Ischemic Conditioning Therapy – Powerful Therapy Awaiting Clinical Adoption. November 2015.

79. *Myocardial ischemia-reperfusion injury: from basic principles to new paradigms*. Distinguished Scientist Lecture, Henry Ford Hospital, Detroit MI, December 2015.

80. *Myocardial ischemia-reperfusion injury: from basic principles to new paradigms*. Visiting Professor, University of Cincinnati Heart, Lung and Vascular Institute, Cincinnati OH, April 2016.

81. *Remote ischemic preconditioning: from observation to hypothesis to discovery.* International Symposium on Ischemic Conditioning and Targeting Reperfusion Injury: A 30 Year Voyage of Discovery. Hospital Universitari Vall d'Hebron, Barcelona Spain, May 2016.

82. *Mechanisms of remote ischemic conditioning: concepts, caveats and controversies.* Visiting Professor, Aarhus University Hospital, Department of Cardiology, Aarhus Denmark, March 2017.

83. *Remote ischemic conditioning: from first evidence. . . to clinical relevance?* Annual Meeting of the International Society for Heart Research (ISHR), North American Section, New Orleans LA, June 2017.

84. *Myocardial ischemia-reperfusion injury: from basic principles to new paradigms*. Visiting Professor, John A. Burns School of Medicine, University of Hawaii, Honolulu HI, February 2018.

85. *Remote ischemic conditioning: trials, tribulations and clinical translation.* Integrative Physiology Symposium: "Ischemic and hypoxic conditioning: Potential for protection of vital organs" at Experimental Biology 2018, San Diego CA, April 2018.

86. *Research networks: the sine qua non to facilitate clinical translation of novel cardioprotective therapies?* Invited Lecturer: 3rd EU-CARDIOPROTECTION COST Action WG Meeting, Santorini Greece, October 2018.

87. *Update on remote ischemic conditioning: trials, tribulations and clinical translation.* ICT Inc., Focus Group Meeting, Chicago IL, November 2018.

88. *Novel strategies to treat 'heart attack': trials, tribulations and clinical translation*. Florida Atlantic University, Boca Raton FL, December 2018.

89. *Remote ischemic conditioning: trials, tribulations and clinical translation.* Preconditioning in Biology and Medicine – Adaptive Responses: the 18th Annual Meeting of the International Dose-Response Society, University of Massachusetts Amherst, Amherst MA, April 2019.

PATENTS:

Light therapy treatment
Patent Numbers: US 8945196; 9610460; 10071261
Patent Assignee: Wayne State University
Inventor(s): Hüttemann, Maik; Lee, Icksoo; Kamholz, John; Grossman, Lawrence; **Przyklenk, Karin**; Sanderson, Thomas
United States Patent and Trademark Office: Issued February 3rd 2015; April 4th 2017; September 11th 2018

EXTERNAL FUNDING (2000 – present):

Current:

"PTHrP receptor stimulation: A novel strategy to protect cardiomyocytes from lethal ischemia-reperfusion injury?"
Radius Health, Inc.
Principal Investigator: **Karin Przyklenk, PhD**
December 2018 – June 2021 $ 339,859
Extended contract under negotiation

"Ultrasound-mediated Controlled Hypoxemic Reperfusion for Inhibition of Reperfusion Injury"
NIH/NHLBI: R01 HL148451
Principal Investigator: Kevin Haworth, PhD
Role in project: Co-Investigator
July 2019 – June 2024 $ 3,866,850

"Macrophages as effectors of cell therapy for heart failure"
NIH/NHLBI R01 HL142579
Principal Investigator: Geoffrey de Couto, PhD
Role in project: Consultant
March 2019 – February 2024 $2,125,000

In revision:

"Protection of vulnerable myocardium in ischemia-reperfusion injury by translational regulation of inflammation with multiplexing nanostructures"
NIH/NHLBI R01 HL149788
Principal Investigator: Samuel A. Wickline, MD
Role in project: Co-Investigator and PI on component of the grant subcontracted to Wayne State University
Previous score = 35 (21st percentile)

"Use of conditioned fresh, frozen, or lyophilized plasma to improve survival and organ function in hemorrhagic shock"
DoD Combat Readiness Medical Research Program (CRRP)
Principal Investigator: Robert A. Kloner, MD PhD
Role in project: Co-Investigator and PI on component of the grant subcontracted to Wayne State University

"Regulation of Opa1 processing: a novel molecular target for myocardial ischemia-reperfusion injury"
NIH/NHLBI R01 HL141328
Principal Investigators: **Karin Przyklenk, PhD** and Thomas Sanderson, PhD

Completed:

"Detroit Cardiovascular Training Program"
NIH/NHLBI: 2 T32 HL120822
Principal Investigator: Jian-Ping Jin, MD PhD
Role: training faculty
January 2019 – January 2024 $ 1,114,230
Role as training faculty ended in 2021 with resignation from Wayne State University

"Ultrasound-mediated oxygen scavenging for inhibition of reperfusion injury"
NIH/NHLBI: K25 HL133452-01
Principal Investigator: Kevin Haworth, PhD
Role: Co-Mentor
July 2016 – June 2020 $ 630,964

"Preventing ischemia/reperfusion damage via noninvasive mitochondria-targeted therapy" DoD Technology/Therapeutic Development Award: PR151051
Principal Investigators: Maik Hüttemann, PhD, Thomas Sanderson, PhD, **Karin Przyklenk, PhD**
September 2016 – August 2019 $ 2,770,837

"Developing Bayesian methods for non-inferiority trial in comparative effectiveness research"
PCORI/ME-1409-21410
Principal Investigator: Samiran Ghosh, PhD
Role: Advisory Board Member
April 2015 – July 2019 $ 832,703

"Thinking outside the (academic) box: career alternatives in cardiovascular sciences
Principal Investigator: **Karin Przyklenk PhD**
BEST Program, Graduate School, Wayne State University
January 2017 – December 2018 $ 4,350

"Preconditioning of human induced pluripotent stem cell-derived cardiomyocytes"
American Heart Association-Great Rivers Affiliate Grant-in-Aid: 16GRNT27100027
Principal Investigator: Mark Angelos, MD
Role: Consultant
January 2016 – December 2017 $ 154,000

"Serelaxin-mediated cardioprotection in human iPSC-derived cardiomyocytes"
Novartis, Inc.
Principal Investigator: **Karin Przyklenk PhD**
April 2016 – September 2017 $ 216,410

"Deciphering the cardiorenal effects of serelaxin in acute heart failure: a canine model"
Novartis, Inc.
Principal Investigator: Philip Levy, MD
Role: Co-Investigator, responsible for quantitative assessment of plasma/serum and cardiac markers of cardiomyocyte stress and injury.
July 2014 – March 2018 $ 1,226,604

"Improving outcome following 'heart attack': the diabetes dilemma"
Principal Investigator: **Karin Przyklenk PhD**
Helen L. Kay Charitable Trust
Awarded July 2013 (no fixed project dates) $ 10,000

"Novel antithrombotic diadenosine tetraphosphate analogs"
NIH/NHLBI R44 HL088828 (SBIR Phase II)
Principal Investigator: Ivan Yanachkov, PhD
Role: Co-investigator and PI on component of the grant subcontracted to Wayne State University
July 2013 – June 2017 $ 3,362,169

"Preconditioning improves coronary patency"
NIH/NHLBI: R01 HL072684
Principal Investigator: **Karin Przyklenk, PhD.**
September 2009 – June 2016 $ 1,511,680

"Does serelaxin have a direct, cardioprotective effect? Pilot study in cultured cardiomyocytes"
Principal Investigator: **Karin Przyklenk PhD**
Novartis, Inc.
May 2014 – March 2015 $ 66,434

"Test of article GLSAP4A9 by rat in vivo impedance aggregometry : extended dose assessment"
GLSynthesis, Inc.
Principal Investigator: **Karin Przyklenk, PhD**
September 2013 – December 2014 $ 28,995

"Cardiovascular adaptation and disease prevention: development of a multi-disciplinary translational research team"
Principal investigator: J-P Jin, MD PhD
Wayne State University Multi-disciplinary Group Incubator Program
October 2010 – September 2014 $ 720,000
Role: PI of Project 3 – Co-morbidities in ischemic-reperfused myocardium

"Assessment of platelet closure times in the Emergency Department: a potential guide for the diagnosis and risk-stratification of patients with potential cerebral vascular accidents"
Siemens, Inc.
Principal Investigators: Robert Welch, MD, Claire Pearson, MD, **Karin Przyklenk PhD**
February 2012 – September 2014 $ 26,923

"Photobioinhibition of mitochondrial complex IV: a novel approach to reduce neonatal cerebral ischemia/reperfusion injury"
Principal Investigator: Christian A. Reynolds
American Heart Association-Midwest Affiliate: 12PRE12050312 (Predoctoral Fellowship)
July 2012 – June 2014 $ 52,000
Role: Co-Mentor

"Acute Cardiovascular Stress and Quality of Patient Care"
Principal Investigators: Bengt Arnetz, MD, Philip Lewalski, MD, **Karin Przyklenk PhD**
Blue Cross-Blue Shield of Michigan Foundation-Physician Investigator Research Award
February 2012 – May 2014 $ 10,000

"Autophagy, adenosine and pyruvate protection during heart surgery"
Principal Investigator: Robert M. Mentzer, Jr., MD
NIH: R01 HL034579
September 2009 – May 2013 $ 1,884,966
Role: Co-Investigator and PI on component of the grant subcontracted to Wayne State University

"Novel antithrombotic diadenosine tetraphosphate analogs"
Principal Investigator: Ivan B. Yanachkov, PhD
NIH: 2R44HL088828-02 (SBIR)
August 2009 – December 2012 $ 779,748
Role: Co-Investigator and PI on component of the grant subcontracted to Wayne State University

"Cardioprotection: proof of concept in a porcine model"
Principal Investigator: Roberta A. Gottlieb, MD
NIH: R43 HL095199 (SBIR)
April 2009 – October 2010 $ 142,000
Role: Co-Investigator and PI on component of the grant subcontracted to Wayne State University

"Aging, adenosine and platelet-mediated thrombosis"
Principal Investigator: **Karin Przyklenk, PhD.**
NIH: R21 AG027899
April 2007 – March 2010 $ 358,751

"Effect of small molecule 5-HT_{2A} receptor inhibitor on recurrent thrombosis: dose-response"
Principal Investigator: **Karin Przyklenk, PhD**
Arena Pharmaceuticals
2007 – 2009 $ 268,318

"Preconditioning improves coronary patency"
Principal Investigator: **Karin Przyklenk, PhD.**
NIH Director's Bridge Award: R56 HL072684
May 2007 – August 2009 $ 393,750

"Platelet reactivity in acute chest pain: implications for risk stratification"
Principal Investigator: Chad E. Darling, MD
Society for Academic Emergency Medicine (SAEM) Research Training Grant
July 2007 – June 2009
Role in project: Mentor $ 150,000

"Laser acupuncture"
Principal Investigator: Peter Whittaker, PhD.
NIH: R21 AT002405
May 2005 – April 2008 $ 440,000
Role in project: Co-Investigator

"Cardioprotection with 'postconditioning': loss of efficacy in the diabetic heart?"
Principal Investigator: **Karin Przyklenk, PhD.**
NIH: 3 P30 DK032520-23S1
NIH-NIDDK-UMASS Diabetes & Endocrinology Research Center Pilot & Feasibility Program
April 2006 – March 2008 $ 110,000

"Preconditioning improves coronary patency"
Principal Investigator: **Karin Przyklenk, PhD.**
NIH: R01 HL072684
May 2002 – April 2007 $ 853,125

"Stuttering reperfusion: a novel treatment for heart attack"
Principal Investigator: **Karin Przyklenk, PhD.**
Worcester Foundation for Biomedical Research
July 2004 – December 2005 $ 25,000

"Role of inositol trisphosphate in preconditioning"
Principal Investigator: **Karin Przyklenk, PhD.**
NIH: 1 R01 HL063713
December 2001 – November 2006 $ 853,125

"Preconditioning the aged heart: efficacy and mechanisms"
Principal Investigator: **Karin Przyklenk, PhD.**
NIA: R03 AG017758
October 1999 - February 2001 $ 80,566